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A series of related N3S 
99mTc-peptide complexes were synthesized and tested for use in 
pretargeting SPECT imaging that utilizes the bioorthogonal Diels-Alder click reaction between 
tetrazine (Tz) and transcyclooctene (TCO). The objective was to optimize the excretory 
pathways of the 99mTc-peptide complexes for maximum tumor targeting with the in vivo “click” 
and minimum non-target uptake. The 99mTc–tetrazine constructs were prepared by reaction of 
99mTc-peptide complexes (99mTc-FKC, 99mTc-FKCR, 99mTc-DKC, and 99mTc-SKC) with Tz-NHS 
or Tz-PEG5-NHS to form 
99mTc FK(Tz)C, 99mTc-FK(PEG5-Tz)CR, 
99mTc-DK(PEG5-Tz)C, and 
99mTc-SK(PEG5-Tz)C. Log P values were obtained to determine hydrophilicity of each complex. 
Bovine serum albumin (BSA) was modified with TCO, reacted with each complex, and the 
“click” reaction was confirmed using Radio-TLC. Biodistributions and blood half-life studies 
were then performed on healthy athymic mice to determine which complex exhibited the optimal 
excretory characteristics. The Radio-TLC results indicate that each complex contains a viable Tz 
moeity. The biodistribution results suggest that 99mTc-FK(PEG5-Tz)CR has the most promising 
excretory pathway wherein excretion through the gut and intestines is minimized. The blood 
half-life values obtained indicated that clearance from the blood is not likely too fast to prevent 
v 
 
the in vivo “click” reaction from occurring. Mice bearing xenografted SW1222 tumors were 
pretargeted with A33-TCO followed by the 99mTc-peptide-Tz complexes. SPECT/CT images 
were obtained and the in vivo “click” was confirmed for both 99mTc-FK(Tz)C and 99mTc-
FK(PEG5-Tz)CR. 
99mTc-FK(PEG5-Tz)CR exhibited higher tumor:background ratios than did 
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1.1. Pretargeting General Background 
 
 Ever since Sam Seidlin demonstrated the potentially life-saving benefits of nuclear 
medicine in 1946, scientists and physicians have been actively working to expand the availability 
and efficacy of these treatments.1 When the technetium-99m generator (99Mo/99mTc) was 
developed in the 1960s, it allowed 99mTc to develop into the ubiquitous imaging agent that it is 
today. Both the therapeutic and diagnostic sides of nuclear medicine have come a long way over 
the decades and the range of radioisotopes considered for clinical use continues to expand. 
Among the isotopes commonly used in nuclear medicine are 99mTc, 123I, 131I, and 111In for single-
photon emission computed tomography (SPECT) imaging, 13N, 18F, 68Ga, 89Zr, and 82Rb for 
positron emission tomography (PET) imaging, and 90Y, 131I, and 177Lu for therapy. Many others 





Table 1: Selection of common radioisotopes used for nuclear medicine imaging. 
  
Radionuclide Half-life Imaging Type
111
In 2.80 d SPECT
123
I 13.2 h SPECT
131I 8.02 d SPECT
133Xe 5.25 d SPECT
201Tl 3.05 d SPECT
67Ga 78 h SPECT
99mTc 6.01 h SPECT
11
C 20.3 m PET
124
I 4.18 d PET
13N 9.97 m PET
15O 122.24 s PET
18F 109.7 m PET
38K 7.64 m PET
62Cu 9.67 m PET
64Cu 12.7 h PET
68
Ga 68 m PET
82
Rb 1.27 m PET
89Zr 78.41 h PET





Table 2: Selection of common radioisotopes with therapeutic potential. 
 
 Although some radiopharmaceuticals, mostly imaging agents, do not need targeting 
vectors and  rely only on their natural biodistribution, e.g. 99mTc sestamibi has high cardiac 
uptake and is therefore used to image the heart, radiolabeling specific targeting vectors can 
expand the number of available targets while improving image quality and/or therapeutic 
outcomes. Chief among targeting vectors are monoclonal antibodies (MAbs), which can be 
humanized to avoid immunogenic response and are highly specific to a given antigen. Although 
directly radiolabeled MAbs can be used to great effect for imaging, radioimmunoguided surgery, 
and radioimmunotherapy, MAbs’ long serum half-lives mean that only isotopes with multi-day 
physical half-lives are appropriate.2 This leads to the primary justification for pursuing 





90Y 64 h β-
67
Cu 61 h β
-
188
Re 17 h β
-
186Re 90 h β-
177Lu 161 h β-
131I 8.02 d β-
225Ac 10.0 d α
223
Ra 11.4 d α
213
Bi 0.76 h α
212Bi 1.01 h α
211At 7.21 h α
111In 67 h Auger
Selection of Radioisotopes with Therapeutic Potential
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lived isotopes (e.g. 64Cu and 99mTc) can be used without delivering too high a dose to the patient. 
Furthermore, non-target dose can be minimized while high target uptake is maintained, 
regardless of the radioisotope used. To appropriately introduce the pretargeting system employed 
in this work, an in-depth review of pretargeting in general is in order. Although several excellent 
pretargeting reviews have been published, this introduction will seek to synthesize and expand 
on these, providing the necessary context for evaluating the benefits and limitations of the 
subsequent research results.2-4 
Do you think you should introduce pretargeting here in more detail than just the above sentences.  
 
1.2. Streptavidin and Biotin 
 
 One of the earliest pretargeting systems developed made use of avidin/streptavidin and 
biotin. Before looking more closely at the effectiveness of this system, it is worth laying out 
some details about its components.  
 Biotin is a 244-D vitamin found in low concentrations (~2000 fmol/ml) in tissue and 
blood.5  Clinical interest in developing better assays for measuring in vivo biotin levels increased 
after biotin-responsive inborn errors of metabolism and biotin deficiencies during parenteral 
alimentation were highlighted in the literature.5 Both earlier and improved biotin bioassays made 
use of avidin, a 66-kD tetrameric protein found in the egg whites of birds, reptiles, and 
amphibians.5-6 Each of avidin’s homotetrameric subunits forms an extremely powerful bond with 
biotin with an association constant of 10-15 M.6 Both the rapidity of this interaction and the 




 Streptavidin is a 60-kD tetrameric protein found in Streptomyces avidinii with an 
association constant (10-15 M) comparable to that of avidin.7 Notably, streptavidin is not 
glycosylated and therefore shows lower non-specific binding to tissues than avidin.6, 8-9 This 
advantage has led to more clinical trials being undertaken with streptavidin than with avidin.10-11 
With this said, streptavidin shares the potential for a negative immunogenic response with avidin 
given that both are foreign proteins that cannot be humanized, which limits the potential for 
repeated treatment in the clinic.12   
 Around the same time that avidin/streptavidin and biotin pretargeting systems were being 
explored, an alternative strategy was considered wherein MAbs were modified with biotin 
moieties (biotinylated-MAb), radiolabeled, injected into patients, and then after some time avidin 
was used to clear the remaining activity from the blood.13 This method was tested in the clinic 
with twenty patients suffering from primary or recurrent colorectal cancer.13 Thirteen patients 
were treated with one 123I-biotinylated-MAb, FO23C5 (anticarcinoembryonic antigen), and 
seven patients were treated with another 123I-biotinylated-MAb, B72.3 (antitumor-associated 
glycoprotein 72), before treatment with cold avidin (48 hours post MAb injection and then again 
one to two days before undergoing Radioimmunoguided Surgery (RIGS)).13 This strategy 
successfully reduced the circulation time of the radioactive agent and allowed patients to 
undergo RIGS one week after MAb injection, as opposed to four weeks when directly labeled 
MAbs were allowed to clear on their own.13 Although this demonstrated the benefits of including 
avidin/streptavidin and biotin in targeting regimes by allowing sooner RIGS and reducing non-
target dose, both of these benefits were further improved with pretargeting. 
 Pretargeting with avidin/streptavidin and biotin has been performed using both a two-step 
and three-step protocol. The two-step protocol involves modifying a MAb with either a biotin 
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moiety or avidin/streptavidin moiety (avidinylated/streptavidinylated-MAb). The modified MAb 
is injected into the patient, followed some time later by the corresponding radiolabeled 
avidin/streptavidin or radiolabeled biotin (Figure 1 and Figure 2). This method was also tested 
with fifteen patients with ovarian carcinoma.14 They were injected with 2 mg biotinylated-MAb, 
MOv18 (folate receptor α MAb), followed by 100-150 μg 111In-radiolabeled streptavidin (280-
370 MBq/mg) three to five days later.14  The tumors were imaged 2 to 48 hours after the final 
injection and underwent surgery an average of 3 days later.14 The tumor to non-target uptake of 
9:1 for intraperitoneal samples and 45:1 for extraperitoneal samples represented improvements 
over standard targeting methods.14 Additionally, one animal study showed a total increase in 
%ID/g from 6% for directly radiolabeled MAbs to 24% for biotinylated-MAbs and radiolabeled 








Figure 2: Pretargeting with avidinylated/streptavidinylated-mAb and radiolabeled biotin. 
 
 Despite the benefits of using pretargeted biotinylated-MAbs and radiolabeled 
avidin/streptavidin over directly labeled MAbs, the alternative arrangement was found to be 
preferable. A pharmacokinetic examination of both approaches revealed that maximum molar 
concentrations of radioisotope are obtained on the tumor much more quickly for radiolabeled 
biotin pretargeted with streptavidinylated-MAbs than for radiolabeled streptavidin pretargeted 
10 
 
with biotinylated-MAbs or directly radiolabeled MAbs.17 Supporting this result, the clinical 
efficacy of radiolabeling the biotin was demonstrated in ten patients with squamous cell 
carcinoma of the lung.18 These patients received 1 mg of streptavidinylated-MAb, HMFG1 
(human milk fat globule antigen 1), followed by 50 or 1000 μg 111In-radiolabeled biotin two to 
three days later.18 Images were able to be obtained within 2 hours of 111In-biotin administration 
and non-target uptake was reduced across the board.18 Notably, there is always a concern that 
endogenous biotin will saturate the binding sites of the streptavidinylated-MAbs, blocking the 
subsequent radiolabeled biotin. In this case, however, the authors determined that the biotin 
binding capacity of the circulating streptavidinylated-MAbs was not saturated by endogenous 
biotin in three out of four of the patients after one to three days.18 Despite these findings, the 
potential importance of clearing endogenous biotin for this type of protocol has been highlighted 
in the literature.2  
 One group used a biotin-galactose-human serum albumin clearing agent between 
treatment with streptavidinylated-MAbs and 90Y/111In-biotin for pretargeted radioimmunotherapy 
(PRIT).19 Despite showing that their PRIT strategy improved tumor:background ratios over 
standard radioimmunotherapy (RIT), these investigators noted that the binding capacity of the 
prelocalized streptavidinylated-MAbs decreased over time.19 Interestingly, they asserted that this 
was not caused by endogenous biotin, but rather by biotin released from the liver after 
metabolism of the clearing agent.19 While this theory was not tested further and is far from 
certain, it highlights a potential complication with trying to improve the two-step protocol using 
a clearing agent. 
 The three-step protocol involves 1) injection of a biotinylated-MAb, 2) injection with 
avidin/streptavidin, and 3) injection with a radiolabeled biotin (Figure 3). In the first step, the 
11 
 
biotinylated-MAb will be allowed to circulate for long enough to achieve maximum tumor 
localization.20 Since maximum localization occurs before sufficient blood clearance, the second 
step is necessary to clear circulating biotinylated-MAbs by promoting metabolism of the avidin-
biotinylated-MAb complex in the liver.20 This is known as the “chase effect” and was shown to 
be effective in earlier animal studies.21 The second step will also see the tumor-bound 
biotinylated-MAbs avidinated, allowing for subsequent targeting with radiolabeled biotin as the 
third and final step.20 This not only circumvents the issues with using radiolabeled 
avidin/streptavidin, i.e. long circulation times, but also allows cross-linking at the tumor site, 
promoting retention and internalization of the radioisotope. This strategy takes advantage of the 
tetrameric nature of avidin/streptavidin and significantly reduced tumor to background ratios in 




Figure 3: Three-step protocol using biotinylated-MAb, avidin/streptavidin, and radiolabeled biotin. 
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 The three-step protocol was tested in humans in multiple studies. The first was performed 
with 20 colorectal cancer patients who were 1) injected with 1 mg biotinylated-MAb, FO23C5, 
2) injected with 4-6 mg cold avidin 3 days later, and then 3) injected with 0.2-.3 mg 111In labeled 
biotin (2-3 mCi) 48 hours later.20 All metastases were successfully imaged and the potential 
clinical benefits were clearly demonstrated.20 It was also found to be effective in seven patients 
with uveal melanoma, improving diagnostic sensitivity over directly radiolabeled MAbs and 
exhibiting lower background activity.22 This study used 1 mg biotinylated-MAb, 224-28S (anti-
melanoma antibody), for step one and 99mTc-PAO-biotin (20 mCi) for the third step.22 The 
improvements in resulting clinical SPECT imaging were confirmed with a larger cohort of 15 
uveal melanoma patients.23  
 Moving beyond imaging, the three-step protocol successfully facilitated RIT treatment. A 
test case with a patient diagnosed with advanced oropharyngeal cancer, T4N3M0 squamous cell 
carcinoma, who was treated with 1) 10 mg biotinylated-FO23C5 and 20 mg biotinylated-B72.3, 
2) 50 mg streptavidin 36 hours later, and 3) 1 mg 90Y-biotin (70 mCi) showed notable response 
to treatment with no acute allergic reaction to the MAbs or streptavidin.24 Expanding on this 
promising result, 48 patients with high grade (grades III or IV) glioma were treated with 
biotinylated anti-tenascin MAbs, avidin and streptavidin, and 90Y-biotin using comparable 
methodologies.25 This phase I-II clinical trial significantly improved median survival.25 A 
follow-up study then demonstrated the role that the three-step protocol could play in adjuvant 
treatment of high grade gliomas.26  
 Although the three-step protocol tended to outperform the two-step protocol, it’s 
important to recognize that that is not always the case. It was found that high levels of rapid 
antibody internalization, which occurs with streptavidinylated-MOv18 and streptavidinylated-
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MOv19 complexes, favored two-step protocols.11 Antibody complexes whose internalization is 
promoted and mediated by cross-linking, e.g. streptavidinylated-FO23C5, found more favorable 
outcomes using the three-step protocol.11 
 As noted earlier, immunogenic responses to avidin/streptavidin are a major concern. The 
increase in human anti-streptavidin antibody found after treatment can lead to dangerous allergic 
reactions to further treatment and has been attributed to the loss of interest in this system, in 
favor of pretargeting strategies with fewer potential side-effects and increased potential for 
repeated treatment, where clinically appropriate.2, 18, 27-28 
 
1.3. Complementary Oligonucleotides 
 
 The next pretargeting strategy makes use of complementary oligonucleotides that 
hybridize in vivo (Figure 4). Native phosphodiester DNAs are vulnerable to degradation by 
nucleases and therefore are of limited use.29-31 The earliest oligonucleotide pretargeting efforts 
used a DNA synthesizer to create 15-mers complementary oligodeoxynucleotides wherein the 
5’-end was derivatized for labeling with radioactive iodine (125I) and the 3’ end was 
functionalized for attachment to a MAb.29-30 The terminal modifications were chosen to not only 
facilitate connection to the necessary pretargeting components (i.e. the radioisotope and MAb) 
but also to protect against exonucleases in vivo.29-30 This seems to have been successful because 
the stability of the modified oligonucleotides in human plasma (37°C) increased from 24 hours 
for the unmodified versions to several days.29 Despite this modicum of protection, subsequent 
work has circumvented nuclease degradation altogether by using peptide nucleic acids (PNAs) 




Figure 4: Pretargeting with MAb with oligonucleotide and radiolabeled complementary oligonucleotide. 
  
 PNA is an oligonucleotide that retains DNA nucleobases but replaces the DNA 
phosphodiester backbone with a pseudo-peptide backbone and was designed to recognize double 
stranded DNA via Hoogsteen base pairing.32-33 As non-natural nucleic acid analogues, PNAs 
hybridize with complementary strands quickly and effectively while remaining highly stable in 
vivo and resisting degradation by nucleases/proteases.34-35 Although PNA pretargeting has not 
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progressed to the clinic, a number of promising preclinical studies have shown the potential of 
this strategy. 
 In one such study, an azido derivative of 2,2’-dipicolylamine (Dpa) labeled with 99mTc 
and the cold Re analog was coupled with PNA and tested for in vivo properties.34 The 
radiocomplex, [99mTc(CO)3(Dpa-PNA)], showed favorable characteristics, including relatively 
high hydrophilicity (log Doctanol/water = -0.85 at pH = 7.4), fast blood clearance (0.26 ± 0.1 SUV, 1 
hour post-injection), and high in vivo stability indicated by low uptake in the thyroid and 
stomach in Wister rats.34 In a more recent study, two complementary 15-mer PNA strands, HP1 
and HP2, were tested as pretargeting components for HER2-expressing cells.36 HP1 was 
attached to an anti-HER2 Affibody to form the chimera ZHER2:342-SR-HP1, while HP2 was 
functionalized with a DOTA chelator and tyrosine for labeling with 125I and 111In.36 Subsequent 
tests in BALB/C nu/nu mice with xenografted SKOV-3 (an ovarian cancer cell line) tumors were 
successful with 19 ± 2 %ID/g in the tumors 1 hour post-injection, 50 times higher than the 
activity found in the blood and two times higher than the activity found in the kidneys.37 This last 
point is particularly important given that high kidney uptake is a common concern associated 
with affibody-based therapies.38-40  
 Another group optimized PNA oligomer pretargeting methods through PEGylation, 
lowering kidney and liver accumulation while promoting renal clearance.41 The investigators 
pretargeted A431 epidermoid carcinoma xenografted in NMRI nu/nu mice with 17-mer PNA 
strands attached to epidermal growth factor receptor (EGFR) specific MAbs (cetuximab).41 After 
24 hours, the animals were treated with radiolabeled complementary PNAs. Notably, the 
investigators not only varied the PNA constructs through PEGylation, but also radiolabeled with 
both 99mTc and 64Cu. With the positive results that they presented, their stated goal of testing this 
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system using therapeutic radionuclides (90Y, 177Lu, 186Re, 188Re, etc…) should be followed 
closely. 
 Although the following study was performed years earlier than those just described, its 
novel approach to amplifying the benefits of pretargeting make it stand out.42 A 80 kDa 
poly(methyl vinyl ether-alt-maleic acid) polymer (PA) was modified with ~200 PEGs (in order 
to increase aqueous solubility) and then modified with ~80 PAN strands. The PNA-PA-PEG 
polymer accumulated, through nonspecific diffusion, in xenografted tumors in mice and the 
subsequent administration of 99mTc radiolabeled complementary PNA strands demonstrated that 
amplification efforts can further improve localization for certain pretargeting strategies.  
 The Hnatowich Laboratory has been performing extensive pretargeting studies with 
MORFs for over a decade and a half. As synthetic DNA analogs comprised of DNA bases 
attached to phosphorodiamidate linked methylenemorpholine rings, MORFs exhibit many of the 
same properties that make PNAs attractive, i.e. stable to nucleases and highly specific to 
complementary strands.43 An early study showed that 99mTc labeled MAG3-MORFs (15 and 18 
mer) had rapid pharmacokinetics and could effectively hybridize with complementary strands in 
vivo.44 Soon after, mice with xenografted human colon cancer, LS174T cell line, were 
pretargeted with MORF-MAb, murine anti-CEA antibody MN14, and 99mTc-MAG3-cMORF.
45-46 
Despite relatively high kidney uptake, the tumors were successfully imaged and all other non-
target tissues showed minimal uptake.45-46 Before moving forward, the laboratory investigated 
the source of the higher than expected kidney uptake. It was established that MORFs rich in 
cytosine favored accumulation in the kidney and that choosing cytosine-free 99mTc-MAG3-
cMORFs significantly improved tumor to kidney ratios.47-48  
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 The pretargeting conditions were then optimized using 99mTc before the cytosine-free 
cMORF was radiolabeled with 111In, 90Y, and 188Re in preparation of therapeutic studies.49-52 A 
subsequent preclinical study wherein LS174T tumor-bearing mice were pretargeted with MORF-
MAb, anti-TAG-72 CC49 antibody, and then treated with 188Re-MAG3-cMORF (maximum dose 
of 1.40 mCi) found that this combination acted as an effective radiotherapeutic strategy.53 These 
results were mirrored with 90Y-cMORF soon after.54 Even though these are preliminary studies, 
they show the promise that MORF/cMORF pretargeting could have in the clinic.  
 While exploring this pretargeting system, there were several interesting details that 
emerged beyond the efficacy of the system in and of itself. For one, the investigators compared 
the maximum percent tumor accumulation for three MORF-conjugated antibodies (MN14, 
B72.3, and CC49).55 They found that the maximum percent tumor accumulation of the 
radiolabeled effector was independent of the antibody used for LS174T tumors and that 
optimization of this parameter must be achieved through dosage (of both the MAb and 
radiolabeled components) and timing.31, 55-56 Although antibody characteristics remain important 
for maximum absolute tumor accumulation and tumor to non-target ratios, this study prevented 
the need for additional optimization experiments in this tumor model.55 Another study 
highlighted the effect that the radiolabel can have on pretargeting biodistributions. It was 
determined that 99mTc-cMORF had significantly higher intestinal uptake than did 111In-cMORF, 
despite comparable tumor uptake.57 Looking beyond the radiolabel, they also found that the 
addition of a clearing agent reduces uptake in blood and normal tissues but does not reduce 
tumor uptake.58 Lastly, they determined that the maximum percent tumor accumulation of both 
the MAb and radiolabeled effector were not affected by the size of the tumor.59 While it is 
important to avoid assuming that these results can be extended beyond LS174T tumors and 
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MORF/cMORF pretargeting, they provide food for thought for pretargeting in general and 
display the thoroughness and novelty of the work conducted by the Hnatowich Laboratory. 
 
1.4. Bispecific Antibodies 
 
 Both strategies discussed so far function by modifying intact MAbs with a targetable 
moiety. An alternative approach is possible using bispecific monoclonal antibodies (bsMAbs), 
engineered proteins capable of binding two distinct targets. bsMAbs have been particularly 
helpful in immunotherapy where they are commonly used to recruit T cells to tumor sites, but 
they have been considered for use in pretargeting for decades.4, 60 Although bsMAbs can be 
generated in a number of formats, i.e. comprised of various components to form immunoglobulin 
G (IgG)-like or non-IgG-like molecules, pretargeting efforts have focused on combining various 
Fab region fragments and single-chain variable fragments (scFvs).4, 60 The work has moved from 
anti-tumor Fab’ x anti-chelate-metal Fab’ fragments (1st generation) (Figure 5) to anti-tumor Fab’ 
x anti-chelate-metal Fab’ fragments with divalent radiolabeled hapten-peptides (2nd generation) 
(Figure 6) to anti-tumor F(ab’)2 x anti-HSG Fab with radiolabeled HSG peptides (3
rd generation) 















Figure 7: Pretargeting with anti-tumor F(ab’)2 x anti-HSG Fab with radiolabeled HSG peptides. 
 
 The first clinical investigation into bsMAb pretargeting used the Fab’ fragments of ZCE-
025, an anti-CEA MAb, and CHA-255,  an anti-metal chelate MAb.61 These components were 
chemically linked to form the bsMAb F(ab’)2 which was then injected into 14 patients with 
recurrent or metastatic colorectal edenocarcinoma.61 This construct was allowed to localize at the 
tumor sites for four days before injection with an 111In chelate hapten.61 Despite the successful 
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imaging of hepatic metastatic “hot” spots, the rapid release of the 111In chelate from the tumor 
sites indicated a need for adjustments to the strategy.61-63 
 To improve affinity for the target, and thereby improve retention, it was suggested that 
the radiolabeled chelate hapten could be engineered in such a way that it crosslinks two 
pretargeted bsMAbs.63 The efficacy of this “affinity enhancement system” (AES) was soon 
demonstrated in vivo when divalent haptens were successfully crosslinked on anti-dinitrophenyl 
(DNP) bsMAb pretargeted on spleen lymphocytes in mice.64 The F(ab’)2 bsMAb was developed 
by combining CY34, an anti-Lyb8.2 mouse MAb, with U7.27, an anti-dinitrophenyl (DNP) 
mouse MAb.64 After administration of the resulting bsMAb, the animals were injected with 
either a monovalent or divalent DNP derivatized peptide labeled with either 125I or 111In.64 
Importantly, the divalent haptens outperformed the monovalent haptens and provided early 
justification for continuing investigations into the AES. Furthermore, it was found that the 
bivalent haptens had higher affinity for cell-bound bsMAbs than circulating bsMAbs, reducing 
the need for administration of a clearing agent as an intermediate step.64 
 Taking the work further, the same group tested AES pretargeting in mice xenografted 
with A375 (human melanoma) tumors.65 Pretargeting with the F(ab’)2 bsMAbs and 
111In labeled 
divalent haptens resulted in lower tumor localization but significantly improved 
tumor:background ratios compared to a directly labeled 111In F(ab’)2.
65 The 111In labeled divalent 
hapten also showed higher targeting efficiency than its monovalent correlate both in vitro and in 
vivo.65 An interesting follow-up study demonstrated that these benefits can be further enhanced 
for cells that exhibit two targetable cell-surface antigens.66 In such cases, each antigen can be 
targeted with a separate bsMAb, after which an asymmetric radiolabeled bivalent hapten, which 
contains a single domain to target each bsMAb, will only crosslink cells that are positive for both 
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antigens.66 Because this strategy relies on cells having two readily targetable antigens, it 
exemplifies the potential for personalized pretargeting efforts that could provide additional 
benefits beyond more generalized methods. 
 Moving into the clinic, the AES was shown to be more selective for primary colon 
carcinoma in 11 patients pretargeted with anti-CEA x anti-DTPA bsMAbs and imaged with  111In 
labeled divalent DTPA dimer than the non-AES, in which six patients were imaged with anti-
CEA F(ab’)2 MAbs directly labeled with 
111In.67-68 Years later, another group used the same 
bsMAb/111In labeled divalent DTPA dimer combination to image 44 patients with medullary 
thyroid carcinoma.69 The patients were chosen after elevated levels of circulating calcitonin were 
found following surgical removal of the primary tumor, indicating the potential presence of 
metastases.69 A number of previously unknown metastases were, in fact, discovered and the AES 
pretargeting aided in most of the resulting radioimmunoguided surgeries.69 
 Looking beyond imaging, mice xenografted with TT medullary thyroid cancer and 
treated with 131I labeled divalent DTPA pretargeted with anti-CEA x anti-DTPA F(ab’)2 bsMAb 
showed comparable tumor uptake and reduced non-target toxicity than the directly radiolabeled 
counterpart.70 This translated to a high absorbed dose in small medullary thyroid cancer and 
small cell lung cancer in a preliminary trial in humans, highlighting the potential 
radioimmunotherapeutic benefits of AES in treating micrometasteses.70 
 Despite the notable success of AES, it is an inflexible system in that the bsMAbs must be 
specifically designed to interact with a single chelate complex. A more modular system in which 
radiometals can be easily interchanged to match various clinical conditions and optimize 
outcomes is highly desirable.2, 4 The first key movement in this direction occurred when one 
group designed a group of 125I labeled peptides with bivalent histamine-succinyl-glycine (HSG) 
25 
 
haptens to be used in conjunction with an anti-CEA x anti-HSG bsMAb in in vivo pretargeting of 
xenografted LS174T tumors.71 A similar system was then used with 111In to successfully 
pretarget small cell lung cancer in mice.72 The breakthrough that ushered in the 3rd generation of 
bispecific pretargeting came a few years later, however, when Sharkey et al. showed that the 
HSG-labeled peptide could be modified to not only affect the pharmacokinetics and clearance of 
the hapten complex but to also allow a wide range of SPECT (99mTc, 111In, etc.), PET (124I, 68Ga, 
18F, etc.), and therapeutic radioisotopes (131I, 90Y, 177Lu, etc.).73-75 
 While flexibility afforded by the diHSG-peptides was the most important innovation, the 
system was further improved using trivalent bsMAbs comprised of two tumor binding Fabs and 
one HSG binding Fab. Multiple studies demonstrated the in vivo efficacy of pretargeting with 
trivalent bsMAbs, but the methods used to create these constructs slowed development.4, 76-78 
This difficulty was finally circumvented through the use of dock-and-lock technology, wherein 
an anti-tumor Fab links to another anti-tumor Fab with the aid of a dimerization and docking 
domain, an anti-hapten Fab links to an anchoring domain, and then all three Fabs are secured 
through disulfide bridges.79-81 Dock-and-lock facilitated the creation of additional trivalent 
bsMAbs, which were all found to be effective in in vivo pretargeting with multiple tumor 
systems; the most commonly used bsMAb moving forward was TF2, which is divalent for anti-
CEA and monovalent for HSG.82-87 
 Mice with LS174T xenografted tumors were pretargeted with TF2 followed by a 68Ga 
labeled diHSG-peptide and the resulting images and tissue uptake were compared with that of 
18F-FDG, the gold standard in PET imaging.88-89 Although the 18F-FDG provided clear images of 
the lesions, the 68Ga images were obtained with lower background in non-target tissues, showing 
the desired increase in specificity associated with pretargeting strategies.88-89 These promising 
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results prompted a first-in-human imaging trial a few years later. Five groups of three patients 
were given variable amounts of TF2 followed by 68Ga labeled diHSG-peptide after a variable 
interval.90 This study was able to determine the optimal pretargeting conditions, i.e. a 
bsMAb:peptide mole ratio of 20 and a 30 hour interval, in which high tumor uptake and image 
contrast was obtained.90 
 TF2 was also found to be effective in radioimmunotherapy studies in mice using 177Lu 
labeled diHSG-peptide. The first found limited evidence of non-target toxicity while the second 
used pretargeted 111In immune-SPECT to confirm tumor targeting and track and image the 
delayed tumor growth.91-92 In both cases, survival was prolonged significantly.91-92 177Lu labeled 
diHSG-peptide with TF2 was also tested in a phase 1 clinical trial. The trial was able to establish 
that the pretargeting regimen was safe and that metastatic colorectal cancer can be rapidly and 
specifically targeted in humans.93 Clearly, advances made in pretargeting with bsMAbs have 
increased its clinical potential. 
 
1.5. Bioorthogonal “Click” Chemistry 
 
 The final strategy, pretargeting using bioorthogonal “click” chemistry, harkens back to 
the first two discussed in that it relies on modifying MAbs with pretargeting moieties, as opposed 
to engineering bsMAbs. This strategy is younger than the others, with the most promising work 
only emerging in the last decade, and was selected for use in the original research presented in 
the rest of this paper. Before introducing the inverse electron-demand Diels-Alder (IEDDA) 
reaction that paved the way for recent advances in in vivo pretargeting, it is worth developing an 
understanding of bioorthogonal chemistry in general.  
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  To successfully probe cellular and biochemical processes in vivo a compound needs to 1) 
have no interference or cross-reactivity with naturally occurring moieties (i.e. be bioorthoganol), 
2) be reactive under physiological conditions, 3) be nontoxic, and (if applicable) 4) have a 
minimal effect on the function of any biomolecules that is covalently attached to.94 Many early 
bioconjugation methods made use of thiol-meleimide chemistry or amine-activated ester 
conjugation.94 Despite being successful in vitro, they were not selective enough for in vivo use.94 
The Staudinger ligation, wherein an azide reacts with a triaryl-phosphine to form an amide bond, 
has high selectivity and was an improvement, but was too slow (rate constant = 0.0020 M-1 s-1) 
for most in vivo applications.94-97 As the search for sufficiently fast bioorthogonal reactions 
continued, the strain-promoted azide-alkyne cycloaddition (SPAAC) , a copper-free variant of 
the copper(I)-catalyzed Huisgen azide-alkyne cycloaddition (a classic “click” reaction), was 
discovered.98-100 Early versions of this reaction had rate constants comparable to that of the 
Staudinger ligation but modifications to the system improved the rate constant by orders of 
magnitude.101 This led to a number of successful cyclooctyne reagents being used to label azide-
modified biomolecules both in vitro and in vivo (in live Caenorhabditis elegans, zebrafish, and 
mice), but remained too slow for effective in vivo pretargeted imaging or therapy.95, 102 Building 
off SPAAC, strain-promoted alkyne-nitrone cycloadditions (SPANC) achieved rate constants as 
high as 60 M-1 s-1 and found use in protein and cell surface labeling.101, 103 This comparatively 
fast reaction could not compare with the one reaction that would end up making in vivo 
pretargeting with bioorthogonal chemistry not only feasible but also an attractive alternative to 
the previously discussed strategies, however. 
 This innovative reaction was the inverse electron demand Diels-Alder (IEDDA) [4+2] 
cycloaddition of 1,2,4,5-tetrazines (Tz) and trans-cyclooctene (TCO). First developed in 2008 by 
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Blackman, Royzen, and Fox, the IEDDA reaction was bioorthogonal and exceptionally fast (rate 
constant = 2000 M-1 s-1).104 The syntheses of the IEDDA reactants were quickly optimized and 
the reaction was shown to effectively pretarget and image live tumor cells in vitro.105-108 In 2010, 
Rossin et al. injected LS174T tumor-bearing mice with CC49 MAbs modified with TCO (CC49-
TCO) followed 24 hours later by an 111In labeled Tz.109 Importantly, the resulting SPECT/CT 
images and biodistributions revealed that this in vivo pretargeting strategy was highly effective, 
which led to a considerable number of imaging and/or therapy studies in mice using various 
radioisotope-chelate complexes modified with Tz and targeting vectors modified with TCOs. 
Although only some of these systems had favorable enough pharmacokinetic and clearance 
properties to indicate potential for translation to the clinic, they all confirmed the Tz-TCO 
“click” reaction in vivo and cemented bioorthogonal “click” chemistry’s place as a viable 
pretargeting strategy (Figure 8). To organize the discussion of these in vivo IEDDA studies, 
systems targeting specific xenografted tumor types will be explored separately followed by those 




Figure 8: Pretargeting with TCO-MAb and radiolabeled-Tz. 
 
 Quickly following the in vivo success of Rossin et al., Zeglis et al. pretargeted SW1222 
colorectal cancer xenografts with huA33, a humanized MAb that targets a transmembrane 
glycoprotein (A33 antigen) found in 95% of human colorectal cancers and has a slow cellular 
internalization rate, modified with TCO (A33-TCO).110-112 After allowing the A33-TCO to 
accumulate for 24 hours, they injected 64Cu-NOTA-Tz and performed biodistributions and PET 
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imaging.112 Not only did the images clearly differentiate the tumors, but the biodistributions 
showcased the benefits of pretargeting. The activity was well-retained in the tumor (4.1 ± 0.3 
%ID/g 12 hours post-injection) and although the total tumor uptake was lower than what was 
observed for A33 directly labeled with 64Cu and 89Zr, the dose to non-target tissues was 
significantly lower.112 Adapting this success for PRIT, SW1222 tumor-bearing mice were 
pretargeted with A33-TCO and then treated with 177Lu-DOTA-PEG7-Tz.
113 24 hours after 
treatment, 21.2 %ID/g ± 2.9 was retained on the tumor with low uptake in non-target tissues.113 
Improvements in survival, reductions in tumor volume, and favorable dosimetric profiles 
combined to show the high degree of promise that this treatment strategy could make its way into 
the clinic. 
 Using the same type of xenografted tumors used in the seminal Rossin et al. study 
(LS174T), Devaraj et al. confirmed the IEDDA in vivo “click” reaction using A33-TCO and 18F 
labeled polymer modified Tz.114 Garcia et al. also confirmed the in vivo “click” on LS174T using 
CC49-TCO and 99mTc-HYNIC-Tz, but unfavorable clearance (high uptake and retention in the 
large intestines, kidneys, and liver) suggested that alternative, more hydrophilic 99mTz complexes 
would need to be investigated.115 Another group had more luck pretargeting LS174T tumor-
bearing mice with AVP04-07 diabodies modified with TCO and 177Lu-DOTA-Tz.116 The 
investigators observed relatively high tumor uptake (6.9 %ID/g) with a tumor:kidney ratio of 
6:1.116 The low renal uptake is important given the propensity of diabodies to be retained in the 
kidneys.116 Although these results are less striking than those seen in the more comprehensive 
study performed later by Membreno et al., they highlight the potential for PRIT with 
bioorthogonal “click” chemistry in a different tumor system.113 
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 The next xenografted tumor system that has been studied with IEDDA pretargeting is 
BxPC3, a human pancreatic cancer cell line. In the first study, the tumor-bearing mice were 
pretargeted with 5B1, an anti-CA19.9 MAb, modified with TCO and imaged with 
Al[18F]NOTA-PEG11Tz.
117 The tumors were clearly visualized with PET and 6.4 %ID/g 
remained in the tumor four hours post-injection.117 Additionally, the effective dose was 60 times 
lower than that of directly labeled 89Zr-DFO-5B1.117 A year later, a PRIT study with 5B1-TCO 
and 177Lu-DOTA-PEG7-Tz found rapid (4.6 ± 0.8 %ID/g four hours post-injection) and 
persistent (16.8 ± 3.9 %ID/g 120 hours post-injection) tumor uptake along with fast blood 
clearance, minimal nontarget uptake, and favorable dosimetry.118 
 The final tumor system used HER2-expressing SKOV-3 ovarian cancer xenografts and 
pretargeted with anti-human epidermal growth factor receptor 2 (HER2) affibody molecule Z2395 
modified with TCO.119 The in vivo “click” was confirmed for both 177Lu-DOTA-PEG10-Tz and 
111In-DOTA-PEG10-Tz and the 
111In pretargeting led to a 56-fold decrease in renal uptake 
compared to affibodies directly labeled with 111In.119 Once again, this is notable given the 
propensity of affibody molecules to be absorbed and retained in the kidneys, which are 
particularly sensitive to damage from radioactive dose. 
 The last set of studies used IEDDA “click” reactions to pretarget non-tumor targets. The 
first allowed TCO-modified silica nanoparticles to passively accumulate in mouse lungs before 
injecting a 11C labeled Tz.120 The lungs should a marked increase in %ID/g, which was supported 
with PET imaging.120 Although these results were less exciting in and of themselves when 
compared with some of the imaging studies already discussed, the addition of a 11C-Tz to the 
chemical tool kit is noteworthy.  
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The next two studies modified bisphosphonate with TCO (BP-TCO) to target regions of 
active calcium metabolism and confirm the in vivo IEDDA “click.” The first confirmed the 
“click” with both a 99mTc and 177Lu labeled Tz, which was retained in the knees and shoulders 
with pretargeting but not observed in the skeleton and joints when administered without the BP-
TCO.121 The second confirmed the “click” between 99mTc-HYNIC-Tz and BP-TCO but then 
went on to use the same radiolabeled complex to successfully image Staphylococcus aureus 
infections pretargeted with a TCO modified vancomycin derivative.122  
 Although there has been considerable progress in in vivo pretargeting with bioorthogonal 
IEDDA “click” chemistry, optimization efforts are on-going. The most comprehensive study was 
performed by Meyer et al. wherein optimal structural characteristics of radioligands were 
investigated.123 The parameters investigated included various forms of Tz, linkers (PEGn and/or 
K, H, R, or D amino acids), chelators, and radiometals (18F and 68Ga) and the corresponding 
effects on serum stability, log D, plasma half-life, and molecular charge.123 Biodistributions and 
PET imaging were also performed in order to confirm which combinations provided the best in 
vivo characteristics.123 Notable findings from this paper included: 1) a significant negative 
correlation between Log D values and overall molecular charge was found; 2) complexes with 
larger overall molecular charges cleared more quickly by renal excretion; 3) complexes with 
larger numbers of formally charged components demonstrated more negative Log D values than 
those with the same molecular charge but fewer formally charged components; 4) the lead 18F 
complex, [18F]27, had a net charge of 0 and a Log D of -1.34±0.18; 5) the lead 68Ga complex, 
[68Ga]27, had a net charge of +1 and a Log D of -1.45±0.12; and 6) the lead complexes (by 
definition) achieved the highest target to non-target ratio. 
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An earlier study by Rossin et al. determined that linking a TCO-acetamide derivative to a 
CC49 MAb showed better pharmacokinetic and clearance properties than a CC49 MAb linked 
with a TCO-benzamide.124 The new, more hydrophilic, TCO improved CC49-TCO circulation 
times, improved tumor uptake 1.5-fold, and improved in vivo stability 2.6 fold, despite a 2-fold 
lower reactivity towards Tz.124 More investigations of the effect of the TCO linker have 
produced mixed results. One group used a fluorescent-Tz to test the efficacy of targeting MAb-
PEGn-TCO  in vivo.
125 Those authors found that using no PEG linker was preferable to using 
PEG4 or PEG12 linkers and postulated that while PEGn could improve the accessibility of TCO to 
Tz, it decreased the total number of reactive TCO per MAb.125 This finding conflicted with an 
earlier study that found that the improved accessibility afforded by TCO PEGylation led to a 
greater than 5-fold enhancement in functional density and increased the number of Tz that could 
react with a  given MAb.126 Circumventing this question altogether, Cook, Membreno, and 
Zeglis used a dendrimer scaffold (DEN) to increase the number of TCO moieties per MAb from 
~2 to ~8.127 This strategy more than doubled tumor uptake of [64Cu]Cu-SarAr-Tz pretargeted 
with A33-DEN-TCO (8.9 ± 1.9 %ID/g) over the same radio-complex pretargeted with A33-
PEG12-TCO.
127 
 In an attempt to further improve pretargeting with IEDDA chemistry, Rossin et al. 
developed two Tz-functionalized clearing agents to remove circulating CC49-TCO.128 These 
agents helped optimize 177Lu labeled-Tz treatment of LS174T tumor-bearing mice and 
significantly improved the uptake of Tz on the tumor while decreasing the tumor:blood ratio.128 
More recently, Meyer et al. developed a Tz-modified dextran polymer (DP-Tz) that can scavenge 
circulating MAb-TCO without decreasing tumor uptake.129 The strategy, called “bioorthogonal 
masking,” significantly improved tumor:blood ratios for [68Ga]Ga-NOTA-PEG11-Tz with 5B1-
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TCO and xenografted BxPC3, as well as A33-TCO and xenografted SW1222.129 Importantly, the 
clearing agent was found to be nontoxic and nonimmunogenic, indicating potential for clinical 
translation.129 The improved tumor delineation, enhanced PET image quality, and reduced non-









































2.1. Introduction: 99mTc and 188/186Re  
 
 As indicated by the efforts of multiple groups, technetium-99m is an obvious choice to 
leverage the benefits of and recent developments in pretargeting. This is because 99mTc is a 
ubiquitous imaging agent that accounts for over 80% of global radiopharmaceutical medical 
imaging and has extremely favorable physical characteristics for SPECT.130 Its relatively short 
half-life (t1/2 = 6.0058 hours) means that it causes lower internal radiation dose to patients, 
thereby allowing for a high limit of injectable activity and improved images. Additionally, its 
140 keV photon (emitted with 89% abundance) is easily detectable and has been found to be 
optimal for diagnostic applications in nuclear medicine.131 Lastly, it is comparatively 
inexpensive and widely available; 99Mo/99mTc generators are commercially available and can be 
shipped where needed, even to remote regions.131  
 99mTc is also attractive because it is in the same transition metal group as 188Re and 186Re, 
which both have potential applications as radiotherapeutics.132 188Re can be obtained from a 
generator (188W/188Re) and is relatively inexpensive.131 It has a high-energy 𝛽-emission (2.12 
MeV) with a 17.0 hour half-life, allowing for potentially high dose rates and repeated 
administration for radiotherapy.131 Additionally, with a 155 keV γ-emission (15% abundance), 
188Re can be tracked in vivo and act as a theranostic agent.132 186Re shares this theranostic 
potential, with moderate energy 𝛽-emissions (1.07 and 0.933 MeV) and a low-abundance (9%) 
γ-emission.131 Although 186Re is reactor-produced and not available via a generator, its longer 
half-life (3.7 days) allows transport for potential use as a radiopharmaceutical.132  
Technetium and rhenium have similar physico-chemical and chemical properties, 
allowing many chelators to function effectively for either metal. In fact, . non-radioactive 
(“cold”) macroscopic rhenium  is commonly used as an analog to characterize 99mTc complexes 
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because there are no non-radioactive technetium isotopes. This is all to say that knowledge and 
expertise gained with 99mTc has the potential to be translated to 186Re and 188Re, allowing 
pretargeted radiotherapy in addition to imaging. With this in mind, the overall goal of the 
research undertaken for this dissertation was to develop a viable 99mTc imaging agent that can 
make use of biorthogonal Diels-Alder “click” chemistry for pretargeted SPECT imaging. 
The 99mTc imaging agent is considered viable if it is isolatable, can react in vivo with 
modified antibodies, and produces a high tumor-to-background ratio. To accomplish this goal a 
method was developed to complex the ligand with 99mTc while maintaining the integrity of the 
“clickable moiety,” i.e. the Tz. The resulting complex must have favorable clearance, avoiding 
large uptake in the gut and intestines while maintaining a long enough blood half-life to 
accommodate the “click” reaction on the tumor. To characterize the tracer 99mTc imaging agent, 
cold (i.e. non-radiactive) Re analog complexes must be developed and analyzed. 
In order to satisfy these requirements, a peptide-based chelator backbone was chosen to 
complex with 99mTc and subsequently be appended with a Tz moiety. This decision was made in 
the context of a long history of 99mTc-labeled peptides and their derivatives being tested and used 
in nuclear medicine. Before providing additional details on the specific ligand system used in 
this work, it is important to discuss this history and more fully explore the relevant chemistries of 
both Tc and Re.  
 
2.2. 99mTc and 188/186Re peptide complexes 
 
 As a group 7 transition metal on the periodic table, technetium (Tc) has an electron 
configuration of [Kr]4d55s2. Consequently, Tc can accommodate a diverse ligand environment. 




-).132 When 99mTc is eluted from 99Mo/99mTc generators as Na99mTcO4, it must be reduced 
to achieve the +1, +3, +4, or +5 oxidation states most frequently used in 
radiopharmaceuticals.133-140 In general, an appropriate reducing agent (e.g. Sn2+) is reacted with 
99mTcO4
- in the presence of a coordinating ligand, which stabilizes the 99mTc in a lower oxidation 
state.132 Reaction conditions tend to be mild and radiopharmaceutical kits are often prepared for 
clinical use, wherein freshly eluted 99mTcO4
- can be added to pre-manufactured mixtures of 
reducing agents, ligands, and any additional stabilizing and/or catalyzing agents.132 These 
reactions are optimized and tend to yield products with >95% radiochemical purity.132 Due to its 
similar chemistry, 186/188ReO4
- can be reduced in the presence of ligands to form 
radiopharmaceuticals in much the same way as 99mTcO4
- can.132 Rhenium has a lower redox-
potential than Tc, however, requiring approximately two to three orders of magnitude more 
reducing agent than is needed for Tc.131, 141 Furthermore, Re tends to have slower reaction 
kinetics than Tc and requires a lower pH to prevent back-oxidation to ReO4
-.52  
 Following the development of 111In-DTPA-Octreotide (OctreoScan) for the diagnosis of 
somatostatine (SST) receptor-positive tumors in 1994, interest in developing novel peptide-based 
imaging agents for thrombosis, infection, inflammation, and cancer accelerated.131 This is not 
only because peptide-based imaging agents have the potential to target overexpressed receptors 
(e.g. SST, bombesin, and α-melanocyte), but also because they are relatively easy to synthesize 
and modify (allowing for tunable pharmacokinetics) and have low immunogenicity and 
toxicity.131 Additionally, peptides are more robust than larger proteins (e.g. antibodies) and are 
better able to withstand harsher reaction conditions (an important consideration for the synthesis 
of 186/188Re complexes).  
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The first 99mTc peptide-based radiopharmaceutical approved for use in the clinic was 
[99mTcO] apcitide for imaging thrombosis. Apcitide is a 13 amino acid peptide (cyclo-[D-Tyr-
Apc-GlyAsp-Cys]-Gly-Gly-Cys(Acm)-Gly-Cys(Acm)-Gly-Gly-Cys-NH2) that binds to platelet 
glycoprotein receptors (GPIIb/IIIa) (C5).142 The 99mTc is bound by the three amide nitrogens and 
one sulfur in the C-terminal Gly-Gly-Cys segment of apcitide as an N3S complex.
143 The second 
99mTc peptide-based radiopharmaceutical approved by the FDA was [99mTcO]depreotide, which, 
much like 111In-DTPA-Octreotide, contains an SST receptor binding sequence and was used in 
the diagnosis of SST receptor-positive tumors (e.g. non-small cell lung cancer).144 It also 
contains a linear tetrapeptide sequence wherein the 99mTc again forms an N3S complex. 
Additional 99mTc SST-binding complexes have been tested preclinically (e.g. 99mTc-Demotate 
and 99mTc-Mag3-RC-160), but have not advanced into the clinic.
145-146 Adding to these, a few 
188Re complexes have been developed for potential use as radiotherapeutics. This includes 
[188ReO]depreotide, which was designed with a full kit formulation, and 188Re-RC-160 and 
188Re-P2045, both of which showed preclinical tumor suppression efficacy in mouse models.147-
149  
 Beyond SST, attention has been paid to developing bombesin (BBS)/gastrin-releasing 
peptide (GRP), alpha-melanocyte stimulating hormone (α-MSH), neurotensin (NT), and Arg-
Gly-Asp (RGD) based complexes. Some of these, as well as a selection of additional peptide-








99mTc-RP-527 Van de Wiele, et al. 
150 
186/188Re-N3S-5-Ava-BBS(7-14)NH2 Moustapha, et al. 
151 
188Re-P2S2-5-Ava-BBS(7-14)NH2 Gali, et al. 
152 
188Re-Dpr-SSS-BBS(7-14) Smith, et al. 
153 
188Re-(CO)3-labeled BBS(7-14) 
Smith, et al. 154; Smith, 
et al. 155 
99mTc-CGCG-α-MSH Chen, et al. 
156 
99mTc-MAG2-α-MSH Chen, et al. 
156 
99mTc-CCMSH Chen, et al. 
157 
188Re-CCMSH Miao, et al. 
158 
188Re-(Arg11) CCMSH Miao, et al. 
159 
188Re-HYNIC-4B4 Dadachova, et al. 
160 
99mTc(CO)3-NT(8-13) Garcia-Garayoa, et al. 
161 
188Re(CO)3-NT(XI, XII, XIX) Blauenstein, et al. 
162 
99mTc-RGDSCRGDSY Sivolapenko, et al. 
163 
188Re-RGDSCRGDSY Costopoulos, et al. 
164 
99mTc-[E-c(RGDfK)2]2 Guleria, et al. 
165 
99mTc-3P-RGD2 Yan, et al. 
166 
188Re-MAG3-AG 8.0 Gestin, et al. 
167 
186/188Re-IMP-192 Karacay, et al. 
168 
Table 3: 186/188Re and 99mTc peptide-based radiocomplexes. 
 
 
2.3. Research Project Overview 
 
 An N3S chelated 
99mTc-tripeptide (99mTc-phenylalanine-lysine-cysteine-arginine [99mTc-
FKC]) and Re-tripeptide (Re-phenylalanine-lysine-cysteine-arginine [Re-FKC]) were previously 
synthesized and characterized by this laboratory.169 This 99mTc tracer and its analog were chosen 
for potential use as a pretargeted SPECT imaging agent due to the potential for reaction of the 
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terminal amine of the lysine residue    and a N-hydroxysuccinimde ester on a Tz (Tz-NHS), 
which is commercially available.  
 Early in vivo SPECT imaging with 99mTc-FK(Tz)C somewhat visualized the tumor 
confirming the Tz-TCO reaction, but high intestinal uptake indicated that the complex was not 
appropriate for use in the clinic. Consequently, alternative N3S 
99mTc-peptide-Tz complexes were 
tested, with the goal of improving the pharmacokinetic and clearance characteristics and 
obtaining higher tumor:background ratios and clearer SPECT/CT images. Informed by the 
optimization efforts of other groups, PEG linkers between the lysine and Tz were used and more 
charged or polar amino acids were substituted or appended on the peptide chelator.123 
 The tri- and tetra-peptide complexes that were synthesized and compared to the baseline 
characteristics of 99mTc-FK(Tz)C and 99mTc-FK(PEG5-Tz)C were 
99mTc(V)-phenylalanine-
lysine(tetrazine)-cysteine-arginine (99mTc-FK(Tz)CR;), 99mTc(V)-phenylalanine-lysine(PEG5-
tetrazine)-cysteine-arginine (99mTc-FK(PEG5-Tz)CR; Figure 1B), 
99mTc(V)-aspartic acid-
lysine(tetrazine)-cysteine (99mTc-DK(Tz)C; Figure 1C), 99mTc(V)-aspartic acid-lysine(PEG5-
tetrazine)-cysteine (99mTc-DK(PEG5-Tz)C; Figure 1D), 
99mTc(V)-serine-lysine(tetrazine)-
cysteine (99mTc-SK(Tz)C; Figure 1E), and 99mTc(V)-serine-lysine(PEG5-tetrazine)-cysteine 
(99mTc-SK(PEG5-Tz)C; Figure 1F). All eight complexes were reacted with TCO modified 
bovine serum albumin (BSA-TCO) to confirm the integrity of the Tz moieties. The Log P values 
were then determined to confirm the desired increase in hydrophilicity of the six modified 
complexes over the 99mTc-FK(Tz)C and 99mTc-FK(PEG5-Tz)C. Based on this result, the three 
most promising complexes, 99mTc-FK(PEG5-Tz)CR, 
99mTc-DK(PEG5-Tz)C, and 
99mTc-




 The biphasic blood half-lives were measured in addition to the biodistributions in healthy 
athymic nude female mice. 99mTc-FK(PEG5-Tz)CR showed the greatest decrease in intestinal 
uptake and had a blood half-life that was sufficiently long to accommodate an in vivo Tz-TCO 
“click” reaction. These results indicated that 99mTc-FK(PEG5-Tz)CR was the lead complex for in 
vivo imaging efforts and contributed to the decision to allocate more resources (e.g. more tumor-
bearing mice, additional characterization efforts for the Re analog) to its evaluation. However, all 
four complexes (99mTc-FK(Tz)C, 99mTc-FK(PEG5-Tz)CR, 
99mTc-DK(PEG5-Tz)C, and 
99mTc-
SK(PEG5-Tz)C) were used in SPECT/CT imaging of SW1222 tumor-bearing mice pretargeted 

















Figure 9: A. 99mTc-FK(Tz)CR  B. 99mTc-FK(PEG5-Tz)CR   
                 C. 99mTc-DK(Tz)C    D. 99mTc-DK(PEG5-Tz)C 






Synthesis and characterization of 99mTc-peptide 























3.1. Introduction: Structure and bonding of 99mTc and Re peptides 
 
 The reaction of 99mTcO4
- with Sn(II) in the presence of peptides comprised of L amino 
acids forms square pyramidal d2 closed shell diamagnetic complexes, where the TcV=O moiety is 
in the apical position with the N3S donor atoms as the base of the square pyramid.
170-171 It should 
be noted that the amide nitrogens (N2 and N3 in Figure 10) are deprotonated in the Tc/Re 
complex and are counted as a -1 charge to the resulting complex.169 The amine nitrogen (N1) is 
either protonated as shown in Figure 11 or deprotonated depending on the substituents.169 This 
will influence the charge of the metal chelate and, thus, may have importance on the overall 
pharmacokinetics of the 99mTc species.123 The species shown in Figure 11 would have a neutral 
chelate charge (-1 for each amide N, -1 for the thiolate S and +3 for the MV=O group). These Tc 
and Re complexes will be denoted using the single-letter amino acid code. 
 In addition, two diastereomers form: one in which the TcV=O moiety is “syn” to the 
amino acid residues and the other in which the TcV=O moiety is “anti” to the amino acid 
residues.172-177 This is shown in Figure 11. In previous work in this laboratory, it was shown that 
the first peak to elute on an HPLC system consisting of a C18 column in acetonitrile/water (0.1% 
TFA) mobile phase is the “anti” diastereomer and the second peak is the “syn” diastereomer 
(Figure 12).169 Before spending resources to fully separate diastereomers of 99mTc-peptide-
tetrazine complexes, it is more important to tune the physical properties, such as hydrophilicity 
and charges on the periphery, to confirm its clinical potential. Once a viable peptide construct is 
built, the effects of the diastereomers on the biodistributions can be explored.  
 The Zeglis and Lewis laboratories have found that chelate charge can be a contributing 
factor in pharmacokinetics of small molecule radiometal tetrazine complexes.123 As mentioned 
above, this can be complicated in the case of peptide ligands. Through crystallography and NMR 
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studies, previous members of this lab have found that the amine nitrogen can either be protonated 
or deprotonated, i.e. forming a metal amide bond.169 This is illustrated in Figure 13 and Figure 
14. The lysine residue on Re-FKC lowers the pKa of the amine proton so that under 
physiological pH, one would expect mostly the amide species. This should be considered in the 
design of the constructs and needs to be examined by synthesis of the macroscopic Re standard 
to determine the pKas. However, it is possible to completely circumvent this by either: 1) 
capping off the amine nitrogen with methyl groups that would result in an overall neutral charge 
to the chelate or 2) by extending the amine terminus by one or two amino acids that would result 
in an amide bound to the Tc/Re giving an overall negative charge to the chelate (not considering 
any charged residues). In this study, we are writing the N1 as an amide consistent with the past 
studies where the amide species is found under physiological pH.   
 
 
Figure 10: The tripeptide chelated MV=O moeity (where M = 99mTc/Re) forms square pyramidal 
d2 closed shell diamagnetic complexes. N1 and N2 are deprotonated while N1 may either be 








                                                                    A                                                  B 
Figure 11: Two diastereomers formed from the tripeptide chelated MV=O (where M = Tc/Re). 
A is “syn” to the amino acid residues and B is “anti” to the amino acid residues.169 
 
Figure 12: The first peak to elute on an HPLC system consisting of a C18 column in 
acetonitrile/water (0.1% TFA) mobile phase is the “anti” diastereomer (A) and the second peak 




Figure 13: The amine nitrogen of the tripeptide chelated MV=O can either be protonated or 
deprotonated, i.e. forming a metal amide bond.169 
 
 





 99mTc was obtained via Memorial Sloan Kettering Cancer Center, New York, New York, 
as Na99mTcO4, eluted from a 
99Mo/99mTc Generator. Activity measurements were obtained from 
an Atomic Products Corporation Atomlab 100 Dose Calibrator. The ligands, FKC, FKCR, DKC, 
and SKC, were purchased from ABclonal Science, Inc., dimethyl sulfoxide (DMSO), HPLC-
grade acetonitrile, triflouroacetic acid (TFA), and 0.9% NaCl solution were purchased from 
Fisher Scientific. Tin (II) tartrate 99%, tin (II) chloride dehydrate, and d- gluconic acid was 
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purchased from Sigma Aldrich. Deionized water was obtained from a 0.22μm Millipore filtration 
system. All in vivo experiments were performed according to protocols approved by the 
Memorial Sloan-Kettering Institutional Animal Care and Use Committee. 
 
3.3. Syntheses 
3.3.1. Synthesis of 99mTc-FK(Tz)C 
 
 A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter. 
565 μL 99mTcO4
- (80 mCi/565 μL 0.9% saline), 200 μL FKC (2 mg/mL 0.9% saline), and 40 μL 
filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to 
proceed for 10 minutes at 90°C. The product, 99mTc-FKC, was HPLC purified using a Waters 
Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in 
water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at a 
retention time of 16.2-17.1 minutes and taken to dryness using a vacuum line. The product was 
reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 μL DIEA was 
added and the reaction was allowed to proceed for 30 minutes at room temperature. The product, 
99mTc-FK(Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å analytical 
column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and acetonitrile 
(solvent B) mobile phase. The product was collected at a retention time of 27.3-28.6 minutes and 
taken to dryness using a vacuum line. 
 
3.3.2. Synthesis of 99mTc-FK(PEG5-Tz)C 
 
 A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter. 
565 μL 99mTcO4
- (80 mCi/565 μL 0.9% saline), 200 μL FKC (2 mg/mL 0.9% saline), and 40 μL 
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filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to 
proceed for 10 minutes at 90°C. The product, 99mTc-FKC, was HPLC purified using a Waters 
Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in 
water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at a 
retention time of 16.2-17.1 minutes and taken to dryness using a vacuum line. The product was 
reconstituted in 300 μL DMSO. 10 μL Tz-PEG5- NHS (25 mg/mL in DMSO) and 5 μL DIEA 
was added and the reaction was allowed to proceed for 30 minutes at room temperature. The 
product, 99mTc-FK(PEG5-Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å 
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and 
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 25.9-28.1 
minutes and taken to dryness using a vacuum line. 
 
3.3.3. Synthesis of 99mTc-FK(Tz)CR 
 
 A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter. 
565 μL 99mTcO4
- (80 mCi/565 μL 0.9% saline), 200 μL FKCR (2 mg/mL 0.9% saline), and 40 
μL filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed 
to proceed for 10 minutes at 90°C. The product, 99mTc-FKCR, was HPLC purified using a 
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic 
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at 
a retention time of 17.5-18.9 minutes and taken to dryness using a vacuum line. The product was 
reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 μL DIEA was 
added and the reaction was allowed to proceed for 30 minutes at room temperature. The product, 
99mTc-FK(Tz)CR, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å analytical 
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column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and acetonitrile 
(solvent B) mobile phase. The product was collected at a retention time of 26.0-26.8 minutes and 
taken to dryness using a vacuum line. 
 
3.3.4. Synthesis of 99mTc-FK(PEG5-Tz)CR 
 
 A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter. 
565 μL 99mTcO4
- (80 mCi/565 μL 0.9% saline), 200 μL FKCR (2 mg/mL 0.9% saline), and 40 
μL filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed 
to proceed for 10 minutes at 90°C. The product, 99mTc-FKCR, was HPLC purified using a 
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic 
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at 
a retention time of 16.5-17.8 minutes and taken to dryness using a vacuum line. The product was 
reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 μL DIEA was 
added and the reaction was allowed to proceed for 30 minutes at room temperature. The product, 
99mTc-FK(PEG5-Tz)CR, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å 
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and 
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 26.0-27.5 
minutes and taken to dryness using a vacuum line. 
 
3.3.5. Synthesis of 99mTc-DK(Tz)C 
 
 A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter. 
565 μL 99mTcO4
- (80 mCi/565 μL 0.9% saline), 200 μL DKC (2 mg/mL 0.9% saline), and 40 μL 
filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to 
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proceed for 10 minutes at 90°C. The reaction mixture was taken to dryness using a vacuum line  
and reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 μL DIEA was 
added and the reaction was allowed to proceed for 30 minutes at room temperature. The product, 
99mTc-DK(Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å analytical 
column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and acetonitrile 
(solvent B) mobile phase. The product was collected at a retention time of 19.6-21.1 minutes and 
taken to dryness using a vacuum line. 
 
3.3.6. Synthesis of 99mTc-DK(PEG5-Tz)C 
 
 A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter. 
565 μL 99mTcO4
- (80 mCi/565 μL 0.9% saline), 200 μL DKC (2 mg/mL 0.9% saline), and 40 μL 
filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to 
proceed for 10 minutes at 90°C. The reaction mixture was taken to dryness using a vacuum line 
and reconstituted in 300 μL DMSO. 10 μL Tz-PEG5- NHS (25 mg/mL in DMSO) and 5 μL 
DIEA was added and the reaction was allowed to proceed for 30 minutes at room temperature. 
The product, 99mTc-DK(PEG5-Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm 
100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and 
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 20.0-22.3 
minutes and taken to dryness using a vacuum line. 
 
3.3.7. Synthesis of 99mTc-SK(Tz)C 
 
  A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe 
filter. 565 μL 99mTcO4
- (80 mCi/565 μL 0.9% saline), 200 μL SKC (2 mg/mL 0.9% saline), and 
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40 μL filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was 
allowed to proceed for 10 minutes at 90°C. The reaction mixture was taken to dryness using a 
vacuum line and reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 
μL DIEA was added and the reaction was allowed to proceed for 30 minutes at room 
temperature. The product, 99mTc-SK(Tz)C, was HPLC purified using a Waters Symmetry C18 
3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent 
A) and acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 
19.5-21.0 minutes and taken to dryness using a vacuum line. 
 
3.3.8. Synthesis of 99mTc-SK(PEG5-Tz)C 
 
 A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter. 
565 μL 99mTcO4
- (80 mCi/565 μL 0.9% saline), 200 μL SKC (2 mg/mL 0.9% saline), and 40 μL 
filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to 
proceed for 10 minutes at 90°C. The reaction mixture was taken to dryness using a vacuum line  
and reconstituted in 300 μL DMSO. 10 μL Tz-PEG5-NHS (25 mg/mL in DMSO) and 5 μL 
DIEA was added and the reaction was allowed to proceed for 30 minutes at room temperature. 
The product, 99mTc-SK(PEG5-Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm 
100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and 
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 21.3-23.5 







3.4. HPLC Analyses 
 
 All analytical and preparatory HPLC methods used during the syntheses of these 
compounds were performed using a VARIAN ProStar UV-vis HPLC system interfaced with a 
NaI detector and a Tennelec Minibin power supply, high voltage supply, and amplifier.  All 
HPLC experiments monitored the 99mTc γ emissions as well as the absorbance units at λ = 
260nm.  The mobile phase consisted of 0.1% trifluoroacetic acid in (A) H2O and (B) acetonitrile.  
A Waters Symmetry C18 5μm 4.6x100mm column was used with various mobile phase gradients 
(e.g. 5-45% B over 40 minutes). 
 
3.5. Log P Analyses 
 
 To determine the partition coefficients the 99mTc complexes were dried via high vacuum 
system following synthesis. The product was reconstituted in H2O and placed into a micro 
centrifuge tube with an equal amount of 1-octanol. The samples were vortexed and then 
centrifuged at 10,000 rpm for 5 minutes.  Aliquots were taken from both layers and then counted 
on a Perkin Elmer Automatic Wizard γ-counter. The logarithm of the ratio of the activity in the 
1-octanol to the activity in the H2O was then calculated. This procedure was completed in 
triplicate for each complex and the mean values and standard deviations were reported. 
 
3.6. Radio-TLC Analyses 
 
 To avoid wasting huA33-TCO confirming the integrity of the tetrazine moiety for every 
complex, BSA was modified with TCO. The degree of conjugation (TCO/BSA) was calculated 
to be 0.833 by reacting BSA-TCO with Cy5-methyltetrazine and analyzing with UV-vis 
spectroscopy.  Could you give more details including a reference or two.  
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 To confirm the integrity of the tetrazine moiety in each 99mTc  complex, the complex was 
reconstituted in PBS following standard synthesis and high vacuum drying. This complex was 
spotted on a silica gel TLC plate (mobile phase: 50% ACN, 50% H2O, 0.1% TFA) and analyzed 
via radio-TLC. The remaining complex was reacted with BSA-TCO, spotted on a silica gel TLC 
plate, and analyzed via radio-TLC. The reaction mixture was then run through a PD-10 size 
exclusion column, spotted on a silica gel TLC plate, and analyzed via radio-TLC.   
 
3.7. Results and Discussion 
3.7.1. Synthesis and Isolation of 99mTc-peptide and 99mTc-peptide-Tz constructs 
 
 A series of related tri- and tetra-peptide-tetrazine-99mTc complexes were synthesized for 
in vivo testing. This peptide motif was chosen because: 1) the N3S core forms stable technetium 
complexes; 2) judicious choice of amino acids (natural and non-natural) and linkers (PEG and 
others) may allow “tuning” of the pharmacokinetics to optimize tumor uptake and drive the 
clearance through the kidneys which is desirable; 3) the lysine moieties and aspartic acid 
moieties can be derivatized with appropriate tetrazine reagents; and 4) this research group has 
knowledge of the chemistry, including stereochemistry, of Tc and Re complexes of N3S peptide 
constructs. 
 The synthetic approach, detailed in the above experimental section involved: 1) synthesis 
of the 99mTc peptide and purification via HPLC; 2) dry-down of the HPLC fraction to a film of 
the 99mTc peptide; 3) reconstitution of the 99mTc peptide in DMSO and reaction with the 
tetrazine-NHS ester with the lysine of the 99mTc peptide; 4) HPLC purification to collect the final 
99mTc-peptide-tetrazine construct. This approach was used because of the concern that the Sn(II) 
used to reduce 99mTcO4
- would result in decomposition of the tetrazine. This approach involving 
the first HPLC purification removed any excess Sn from the system.  
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It was later determined that Sn(II) may not be as detrimental to the tetrazine moiety as we 
originally thought and it was found that it is possible to eliminate the first HPLC purification (to 
obtain the 99mTc peptide) and simply dry-down the reaction prior to reconstitution in DMSO and 
reaction with tetrazine. This will be discussed in the synthesis of the new hydrophilic analogs. 
Please note, while diastereomers almost certainly form (as discussed previously) for both 
the 99mTc-peptide and 99mTc-peptide-tetrazine complexes, isolating a single 99mTc-peptide-
tetrazine diastereomer is not a priority. Upon reaction with tetrazine, the radioactive peak in the 
HPLC that shifts upon addition of tetrazine was collected. This may be a mixture of both 
diastereomers; however, at this point in the development of a preclinical imaging agent, it is 
more important to obtain any 99mTc-peptide-tetrazine construct that may be useful. Once a viable 
construct is identified with respect to pharmacokinetics, the diastereomeric structure can be 
fleshed out.  Therefore, the basic structure of the 99mTc-peptide-tetrazine constructs are 
represented instead of the specific diastereomers.    
 99mTc-FK(Tz)CR and 99mTc-FK(PEG5-Tz)CR were synthesized using a method similar to 
that used to synthesize 99mTc-FK(Tz)C and 99mTc-FK(PEG5-Tz)C (Figure 15). 
99mTcO4
- was 
obtained from Memorial Sloan Kettering Cancer Center, freshly eluted with saline from a 
99Mo/99mTc generator. The 99mTcO4
- was reduced from 99mTc(VII) to 99mTc(V), to fit in the N3S 
chelate as the 99mTc=O adduct, using a saturated solution of Sn(II) tartrate, filtered with a 0.1μm 
syringe filter, in the presence of L-FKCR.  The reaction was allowed to proceed for 10 minutes 
at 90°C before HPLC purification. The gamma peak believed to be the syn diastereomer due to 
its position on the RP HPLC was collected and taken to dryness under high vacuum.169  The 
product was reconstituted in anhydrous dimethyl sulfoxide (DMSO) and reacted with Tz-NHS 
ester in the presence of N,N-Diisopropylethylamine (DIEA). The resulting 99mTc-FK(Tz)CR 
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complex was purified using HPLC, taken to dryness, and reconstituted in phosphate buffered 
saline (PBS) at a pH of 7.4. 
The major peak of the 99mTc-FKCR HPLC profile was easily isolated and the shift in the 
retention time following the reaction with the tetrazine-NHS ester (Tz-NHS) indicated a 
successful coupling reaction (Figure 16).   
 
 

















Figure 16: Radio HPLC showing 99mTc peptide and 99mTc-peptide-tetrazine. The change in 
retention time using the same solvent gradient on the radio-HPLC from 99mTc-FKCR to 99mTc-
FK(Tz)CR indicates that the 99mTc-FKCR is reacting with the Tz-NHS ester. 
 
 
 The 99mTc-FK(PEG5-Tz)CR reaction scheme is identical to that of 
99mTc-FK(Tz)CR, 
except a tetrazine-PEG5-NHS ester (Tz-PEG5-NHS) is used in place of Tz-NHS.  As before, the 
change in retention time on the radio-HPLC from the 99mTc-FKCR to 99mTc-FK(Tz)CR indicated 
that the 99mTc-FKCR is reacting with the Tz-PEG5-NHS ester. 
 Using the reaction scheme above (Figure 15) and the HPLC system described above, it 
was not possible to sufficiently separate the more hydrophilic 99mTc-DKC from the 99mTcO4
- and 
various side products obtained in the HPLC void peak (
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Figure 17).  
 On the assumption that the 99mTc-DKC was formed but could not be separated using the 
current HPLC system, the reaction with tetrazine was pursued without prior purification. The 
new reaction scheme that eliminated the HPLC purification of 99mTc-DKC is shown in Figure 
18. Notable features in this synthesis are: 1) filtration of the Sn tartrate prior to reaction with 
99mTcO4
-; 2) no HPLC purification of 99mTc-DKC- simply drying down the entire reaction 
mixture containing excess Sn tartrate; 3) reconstitution in DMSO and reaction with Tz-NHS 
ester. 
99mTcO4
- was obtained from Memorial Sloan Kettering Cancer Center. The 99mTcO4
- was 
reduced from 99mTc(VII) to 99mTc(V) using a saturated solution of Sn(II) tartrate, filtered with a 
0.1μm syringe filter, in the presence of L-DKC.  The reaction was allowed to proceed for 10 
61 
 
minutes at 90°C, taken to dryness under high vacuum, reconstituted in anhydrous dimethyl 
sulfoxide (DMSO), and reacted with Tz-NHS ester in the presence of N,N-
Diisopropylethylamine (DIEA). The resulting 99mTc-DK(Tz)C complex was purified using 
HPLC, taken to dryness, and reconstituted in phosphate buffered saline (PBS) at a pH of 7.4. 
The 99mTc-DK(Tz)C HPLC preparation (Figure 18) indicates that while a significant 
percentage of the activity remains unreacted at the void, more than enough 99mTc-DK(Tz)C is 
obtained that can be separated and used for preliminary studies; this is shown in the highlighted 
area of the radiotrace in Figure 19.  
Figure 17: Reaction scheme for the synthesis of 99mTc-DK(Tz)C.  This approach eliminates the 





Figure 18: The radio-HPLC peak suspected to be 99mTc-DKC is too close to the HPLC void 
peak (~3-5 minutes) and is therefore not easily isolated. This HPLC gradient is water and 







Figure 19: Using the modified reaction scheme, the 99mTc-DK(Tz)C reaction mixture was 
analyzed using a radio-HPLC.  The region suspected to contain the 99mTc-DK(Tz)C (highlighted) 
was collected for reinjection. 
 
 The 99mTc-DK(PEG5-Tz)C reaction scheme is identical to that of 
99mTc-DK(Tz)C, except 
that Tz-PEG5-NHS is used in place of Tz-NHS.  The 
99mTc-DK(PEG5-Tz)C had a similar 
retention time to 99mTc-DK(Tz)C. 
A very important finding in this set of experiments is that Sn can be likely utilized 
directly in the reactions without compromising the integrity of the tetrazine. While further 
optimization is required to improve radiochemical yields, this new reaction scheme indicates that 
the Tz-NHS and Tz-PEG5-NHS is less sensitive to the presence of Sn than previously feared. 
This finding is also encouraging for the synthesis of a N3S peptide-tetrazine ligand that can be 
reacted with 99mTcO4
- and Sn(II) in the last step. 
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 Due to the fact that 99mTc-SKC had an HPLC profile similar to that of 99mTc-DKC, the 
new reaction scheme was used to synthesize 99mTc-SK(Tz)C.  The 99mTc-SK(Tz)C and 99mTc-
SK(PEG5-Tz)C was successfully isolated from the reaction mixture. 
 
2.7.2. Radio-TLC Results 
  
 For each complex, the first radio-TLC readout indicates that most of the 99mTc-peptide-Tz 
complex moves with the solvent front while some activity remains at the origin (possibly in the 
form of 99mTcO- or unreacted 99mTc-peptide complex). After reacting with BSA-TCO, most of 
the activity moves to the origin, indicating a successful tetrazine-transcyclooctene “click” 
reaction. This is supported by the fact that the solvent front peak disappears after purification 
using a size-exclusion Sephadex G-25M PD-10 column (2.5 mL dead volume). Based on these 
results all six modified 99mTc complexes contain viable tetrazine moieties that are reactive with 





Figure 20: Radio-TLC of 99mTc-FK(Tz)CR before and after reaction with BSA-TCO and before 




Figure 21: Radio-TLC of 99mTc-FK(PEG5-Tz)CR before and after reaction with BSA-TCO and 





Figure 22: Radio-TLC of 99mTc-DK(Tz)C before and after reaction with BSA-TCO and before 





Figure 23: Radio-TLC of 99mTc-DK(PEG5-Tz)C before and after reaction with BSA-TCO and 






Figure 24: Radio-TLC of 99mTc-SK(Tz)C before and after reaction with BSA-TCO and before 






Figure 25: Radio-TLC of 99mTc-SK(PEG5-Tz)C before and after reaction with BSA-TCO and 
before and after purification with PD-10 size exclusion column. 
 
 
2.7.3. Log P Results 
 
 The first complex tested, 99mTc-FK(Tz)C, was relatively lipophilic, with a Log P value of 
1.0 ± 0.1. Increasing hydrophilicity tends to promote renal clearance and reduce intestinal 
uptake, therefore modifications were made with the aim of lowering the Log P value. 
 For the 99mTc-peptide complexes, the cysteine is necessary to anchor the N3S 
99mTc 
complex and the lysine is required to react with the Tz-NHS ester. Consequently, to increase the 
hydrophilicity of the complex, the phenylalanine (a nonpolar residue) was replaced with an 
aspartic acid (a charged residue) and a serine (a polar residue). This worked, reducing the Log P 
to -2.6 ± 0.2 for 99mTc-DK(PEG5-Tz)C and -0.9 ± 0.3 for 
99mSK(PEG5-Tz)C. As an alternative to 
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replacing the phenylalanine, an arginine (a charged residue) was added to the original complex, 
forming 99mTc-FK(Tz)CR. This also reduced the Log P value to -0.5 ± 0.2 
 In addition to modifying the peptide backbone, the complexes were PEGylated by 
reacting the 99mTc-peptide complexes with Tz-PEG5-NHS instead of Tz-NHS. PEGylation of the 
Tz complexes successfully increased their hydrophilicities, as demonstrated by more negative 
Log P values (Table 4), with the exception of 99mTc-DK(PEG5-Tz)C which had the same Log P 
value as 99mTc-DK(Tz)C. 
 
 
Table 4: Mean logarithms of the partition coefficients of 99mTc complexes. Increased negative 





 All of the relevant 99mTc complexes were successfully synthesized and purified using an 
HPLC system. The integrity of the Tz moieties were confirmed using Radio-TLC and the 
increased hydrophilicity was demonstrated using the Log P values. It was determined that 99mTc-
FK(PEG5-Tz)CR, 
99mTc-DK(PEG5-Tz)C, and 
99mTc-SK(PEG5-Tz)C would be used in 
subsequent in vivo studies to compare against 99mTc-FK(Tz)C. 
Complex Log P













 Although hydrophilicity is not a perfect predictor of whether a complex will clear from 
the kidneys or intestines, more hydrophilic complexes tend to favor renal excretion and the 
comparison of Log P values is a useful test before spending resources on in vivo experiments. 
Similarly, “click” reactions will not necessarily occur in vivo even if the components are viable, 

























Synthesis and characterization of Re-peptide 
























 99mTc is an isotope that is available on the “tracer” level and that feature, along with its 
6.02 half-life, requires that a macroscopic analog be synthesized for complete characterization.  
Due to the similarity of Tc and Re chemistry in the N3S (tripeptide) chelate, the macroscopic 
complex using non-radioactive Re (often called the “cold” standard) were synthesized for each 
of the 99mTc tri and tetra-peptide complexes chosen for in vivo study. These complexes were Re-
FKC, Re-FK(Tz)C, Re-FKCR, Re-FK(PEG5-Tz)CR, Re-DKC, Re-DK(PEG5-Tz)C, Re-SKC, 
and Re-SK(PEG5-Tz)C and each was analyzed using LCMS. NMR analyses were then 
performed on the most promising complex, Re-FK(PEG5-Tz)CR, and its precursor, Re-FKCR. 
Coelutions of the Re and 99mTc complexes were then performed to verify that the macroscopic 




4.2.1. Synthesis of (Bu4N)[ReOBr4(H2O)] •2H2O 
 
 This rhenium starting material was prepared following the method of Rose et. al.178 
Briefly, n-butylphosphine, PBun3 was dissolved in CH2Cl2 before Br2 in CH2Cl2 was added 
dropwise. (Bu4N)ReO4 was then dissolved in CH2Cl2, added to the reaction mixture, and stirred 
for 45 minutes at room temperature. Cyclohexene, diethyl ether, and pentane was added 
sequentially to precipitate the purple product, which was collected via vacuum filtration. The 
resulting (Bu4N)[ReOBr4(H2O)]•2H2O product showed the following IR (ATR, cm
-1)  stretches: 
2959 (s), 2932 (m), 2873 (m), 1466 (s), 1380 (w), 1227 (w), 1103 (vs), 984 (vs), 903 (vs), 812 




4.2.2. Synthesis of Re-FKC 
 
 10.0 mg (16.8 μmol) of peptide (FKC) was reacted with TBA[ReOBr4(H2O)]•2H2O (18.3 
mg, 22.3 μmol) in the presence of sodium acetate (in a molar ratio of 1:0.9:1.8) in 300 μL of 
MeOH. The reaction was allowed to proceed for 60 minutes at 40°C. 700 μL H2O was added to 
the reaction mixture and the solution was stirred. The 1 mL solution was HPLC purified using a 
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic 
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at 
a retention time of 16.2-17.1 minutes and lyophilized overnight to dryness. 
 
4.2.3. Synthesis of Re-FK(Tz)C 
 
 Lyophilized Re-FKC was reconstituted in 300 μL DMSO. Tz-NHS (25 mg/mL in 
DMSO) was added to the solution (in a Re-FKC:Tz-NHS molar ratio of 1:1.1). 5 μL N,N-
diisopropylethylamine (DIEA) was added and the reaction was allowed to proceed for 30 
minutes at room temperature. 500 μL H2O was added to the reaction mixture and the solution 
was stirred. The product was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å 
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and 
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 27.3-28.6 
minutes and lyophilized overnight to dryness. 
 
4.2.4. Synthesis of Re-FKCR 
 
 10 mg (13.3 μmol) of peptide (FKCR) was reacted with TBA[ReOBr4(H2O)]•2H2O (13.7 
mg, 16.7 μmol) in the presence of sodium acetate (in a molar ratio of 1:0.9:1.8) in 300 μL of 
MeOH. The reaction was allowed to proceed for 60 minutes at 40°C. 700 μL H2O was added to 
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the reaction mixture and the solution was stirred. The 1 mL solution was HPLC purified using a 
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic 
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at 
a retention time of 26.0-26.8 minutes and lyophilized overnight to dryness. 
 
4.2.5. Synthesis of Re-FK(PEG5-Tz)CR 
 
 Lyophilized Re-FKCR was reconstituted in 300 μL DMSO. Tz-PEG5-NHS (25 mg/mL in 
DMSO) was added to the solution (in a Re-FKCR:Tz-PEG5-NHS molar ratio of 1:1.1). 5 μL 
N,N-diisopropylethylamine (DIEA) was added and the reaction was allowed to proceed for 30 
minutes at room temperature. 500 μL H2O was added to the reaction mixture and the solution 
was stirred. The product was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å 
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and 
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 26.0-27.5 
minutes and lyophilized overnight to dryness. 
 
4.2.6. Synthesis of Re-DKC 
 
 10 mg (17.8 μmol) of peptide (DKC) was reacted with TBA[ReOBr4(H2O)]•2H2O (20.7 
mg, 25.3 μmol) in the presence of sodium acetate (in a molar ratio of 1:0.9:1.8) in 300 μL of 
MeOH. The reaction was allowed to proceed for 60 minutes at 40°C. 700 μL H2O was added to 
the reaction mixture and the solution was stirred. The 1 mL solution was HPLC purified using a 
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic 
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at 




4.2.7. Synthesis of Re-DK(PEG5-Tz)C 
 
 Lyophilized Re-DKC was reconstituted in 300 μL DMSO. Tz-PEG5-NHS (25 mg/mL in 
DMSO) was added to the solution (in a Re-DKC:Tz-PEG5-NHS molar ratio of 1:1.1). 5 μL N,N-
diisopropylethylamine (DIEA) was added and the reaction was allowed to proceed for 30 
minutes at room temperature. 500 μL H2O was added to the reaction mixture and the solution 
was stirred. The product was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å 
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and 
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 20.0-22.3 
minutes and lyophilized overnight to dryness. 
 
4.2.8. Synthesis of Re-SKC 
 
 10 mg (18.7 μmol) of peptide (SKC) was reacted with TBA[ReOBr4(H2O)]•2H2O (22.5 
mg, 27.4 μmol) in the presence of sodium acetate (in a molar ratio of 1:0.9:1.8) in 300 μL of 
MeOH. The reaction was allowed to proceed for 60 minutes at 40°C. 700 μL H2O was added to 
the reaction mixture and the solution was stirred. The 1 mL solution was HPLC purified using a 
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic 
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at 
a retention time of 3.0-5.2 minutes and lyophilized overnight to dryness. 
 
4.2.9. Synthesis of Re-SK(PEG5-Tz)C 
 
 Lyophilized Re-SKC was reconstituted in 300 μL DMSO. Tz-PEG5-NHS (25 mg/mL in 
DMSO) was added to the solution (in a Re-SKC:Tz-PEG5-NHS molar ratio of 1:1.1). 5 μL N,N-
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diisopropylethylamine (DIEA) was added and the reaction was allowed to proceed for 30 
minutes at room temperature. 500 μL H2O was added to the reaction mixture and the solution 
was stirred. The product was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å 
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and 
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 21.3-23.5 
minutes and lyophilized overnight to dryness. 
 
4.3. HPLC Analyses 
 
 All analytical and preparatory HPLC methods used during the syntheses of these 
compounds were performed using a VARIAN ProStar UV-vis HPLC system interfaced with a 
NaI detector and a Tennelec Minibin power supply, high voltage supply, and amplifier.  All 
HPLC experiments monitored the 99mTc γ emissions as well as the absorbance units at λ = 
260nm.  The mobile phase consisted of 0.1% trifluoroacetic acid in (A) H2O and (B) acetonitrile.  
A Waters Symmetry C18 5μm 4.6x100mm column was used with various mobile phase gradients 
(e.g. 5-45% B over 40 minutes). 
 
 
4.4. LCMS Analyses 
 
 Mass spectral data was obtained on a LCMS system comprised of an Agilent 1200 LC 
system coupled to an Agilent 6340 ion trap mass spectrometer. Samples were injected onto an 
Agilent Zorbax column (SB-C8, 5 uM, 2.1 x 50 mm) using a linear gradient of 5-95% 
acetonitrile in water (0.5% formic acid) over 10 minutes. The samples were prepared by 
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dissolving the lyophilized Re-peptide and Re-peptide-Tz samples in water:acetonitrile solution 





4.5. NMR Analyses 
 
The 1D proton and 2D TOCSY (total correlation spectroscopy) NMR spectra were 
obtained from a Bruker Avance III 600 MHz with a TCI cryoprobe NMR spectrometer with 
chemical shift referenced to H2O, at T=296 K. Re-FKCR, the precursor to the lead complex Re-
FK(PEG5-Tz)CR, and free ligand FKCR samples (5-10 mg) were dissolved in 700 μL D2O. 1D 
proton NMR spectra were collected at 8 scans. 2D TOCSY scans were collected at 2 scans, 256 
increments. 
 
4.6. Coelution of 99mTc and Re constructs 
 
 Purified 99mTc-FKCR, 99mTc-FK(PEG5-Tz)CR, 
99mTc-DK(PEG5-Tz)C, and 
99mTc-
SK(PEG5-Tz) were coeluted with their cold, macroscopic rhenium analogs. Resulting from the 
sequence of the UV and radio detectors in this HPLC system, UV active species are expected to 






4.7. Results and Discussion 
4.7.1. LCMS Results 
 
 The m/z values for the molecular ion [M + H]+ peaks obtained through LCMS analyses, 
along with the molecular weights (MW) calculated from the proposed structures, are included in 
Table 5.   
  
 
Table 5: Theoretical molecular weights for proposed Re-peptide and Re-peptide-Tz structures 





4.7.2. NMR Results 
 
The chemical shift (ppm) values from the 1H NMR spectra of the macroscopic Re-FKCR 
and Re-FK(PEG5-Tz)CR were compared to the free FKCR ligand (Table 6). In order to assist in 
the deconvolution of the 1H NMR chemical shifts and make appropriate assignments, 2D 
TOCSY spectra was obtained (Figure 27 and Figure 29). Although the signals observed were 
not strong enough to assign every hydrogen, particularly for Re-FK(PEG5-Tz)CR wherein low 
yields hampered characterization efforts, the 2D deconvolution was sufficient to identify 
hydrogens in each amino acid of the chelated FKCR complex.  
Theoretical MW (g/mol) Experimental MW (g/mol)













Table 6: 1H NMR chemical shifts (ppm) for Re-FKCR and Re-FK(PEG5-Tz)CR compared to 
the free ligand FKCR. 
FKCR Re-FKCR Re-FK(PEG5-Tz)CR
HN 8.12 - -
Hα (1H) 4.32 4.34 4.38
Hβ (2H) 3.08 3.43 3.38
2,6H-Aryl (2H) 7.27 7.25 7.45
3,5H-Aryl (2H) 7.13 7.25 7.32
4H-Aryl (1H) 7.27 7.25 7.45
HN 7.81 - -
Hα (1H) - 4.74 4.79
Hβ (2H) 1.75 1.9 -
Hγ (2H) 1.26 1.15 -
Hδ (2H) 1.63 1.56 -
Hε (2H) 2.84 2.8 2.95
HN 8.35 - -
Hα (1H) - 4.92 4.90
3.85 3.41
3.4 3.19
HN 8.11 - -
Hα (1H) 4.23 4.11 4.12
1.65 1.72 1.60
1.63 1.62 1.60
Hγ (2H) 1.63 1.61 -










Figure 26: 1H NMR assignment of Re-FKCR. 
 
 





Figure 28: 1H NMR assignment of Re-FK(PEG5-Tz)CR. 
 
 





4.7.3. Coelution Results 
 
 As expected from the arrangement of the HPLC system, the Re-peptide and Re-peptide-
Tz UV traces eluted approximately one minute earlier than the corresponding 99mTc-peptide and 
99mTc-peptide-Tz radio-traces (Figure 30, Figure 31, Figure 32, and Figure 33). This indicates 
that the data obtained for the Re complexes can be used a surrogate for the tracer level 99mTc 
complexes. 
 





Figure 31: Coelution of 99mTc-FK(PEG5-Tz)CR (radio-trace) and Re-FK(PEG5-Tz)CR (260 nm 
UV trace). 
 











 The Re-peptide and Re-peptide-Tz complexes synthesized, Re-FKC, Re-FK(Tz)C, Re-
FKCR, Re-FK(PEG5-Tz)CR, Re-DKC, Re-DK(PEG5-Tz)C, Re-SKC, and Re-SK(PEG5-Tz)C, 
matched the expected HPLC retention times and their theoretical MWs were closely 
approximated by the experimental MWs observed through LCMS. Coelution studies confirmed 
that structural data obtained for the Re analogs could be extended to the 99mTc complexes used 
for subsequent in vivo studies. 
 As noted earlier discussions, two major product peaks were observed for each Re-peptide 
and Re-peptide-Tz HPLC purification. Based on the thorough characterization performed on Re-
FKC in previous work in this laboratory, as well as LCMS analyses, it is believed that these 
peaks correspond to the anti and syn diastereomers, defined by the relative positions of the 
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oxygen on the Re and the lysine in the peptide chelator.169 In all cases, the second peak, likely  
the syn diastereomer, was collected and purified. This diastereomer was produced in a higher 
yield than the anti diastereomer, which contributed to the choice to focus on its characterization 
and the corresponding 99mTc complex for use in vivo. The exact nature of the presumed 
diastereometric relationship is worth exploring in future work, but was less pressing than 

















































 As previously discussed, a pretargeted 99mTc SPECT imaging agent will be considered 
viable if it is isolatable, can react in vivo with modified antibodies, and produces a high tumor-to-
background ratio. All of the complexes tested in vivo, 99mTc-FK(Tz)C, 99mTc-FK(PEG5-Tz)CR, 
99mTc-DK(PEG5-Tz)C, and 
99mTc-SK(PEG5-Tz)C, were isolated and confirmed to have Tz 
moieties that react with TCO. They were chosen over the other complexes, 99mTc-FK(Tz)CR, 
99mTc-DK(Tz)C, and 99mTc-SK(Tz)C, due to their greater hydrophilicities, as demonstrated by 
more negative Log P values, as well as the published benefits of using PEGylated Tz 
complexes.123 
 Biodistribution and blood half-life studies were performed in healthy athymic mice to 
determine which complex exhibited the optimal excretory characteristics and should be allocated 
the greatest resources for subsequent studies in SW1222 tumor-bearing mice. Biodistributions 
and pretargeted SPECT/CT imaging was then performed in these tumor-bearing mice. 
  
5.2. Blood Half-life Methods 
 
 Blood half-life studies were completed for 99mTc-FK(PEG5-Tz)CR and 
99mTc-SK(PEG5-
Tz)C by injecting 50 to 60 µCi of each radiolabeled complex into healthy athymic nude female 
mice 6-8 weeks old intravenously via the tail vein. Mice were sacrificed 5 minutes, 15 minutes, 
30 minutes, 1 hour, 2 hours, and 4 hours post injection (n = 4 for each time point). Terminal 
blood draws were collected via cardiac puncture and the blood was weighed before the activity 
was counted. Counting was performed on a Perkin Elmer Automatic Wizard γ-counter and the 
percent injected dose per gram (%ID/g) was calculated and reported. The biphasic exponential 





5.3. Biodistribution Studies in Healthy Mice 
  
 The biological distribution of the 99mTc-FK(Tz)C complex was determined in healthy 
athymic nude female mice 6-8 weeks old. Approximately 50-60 µCi of the radiolabeled complex 
was injected intravenously into the mice via the tail vein. Mice were sacrificed 30 minutes, 1 
hour, 2 hours, and 4 hour post injection (n = 5 per time point).  The following tissues were 
collected; blood, tail, heart, lungs, liver, spleen, stomach, small intestines, large intestines, 
kidneys, muscle, bone, and skin. The tissues were then counted on a Perkin Elmer Automatic 
Wizard γ-counter and the percent injected dose per gram (%ID/g) was calculated and reported. 





5.2. A33 Modification with TCO 
 
 The A33 antibody was modified with transcyclooctene-NHS as described by Zeglis et. 
al.112 5 mg A33 was dissolved in 500 µL PBS. The pH was adjusted to 8.8 – 8.9 using 0.1M 
NaHCO3. Sufficient TCO-NHS in N,N-dimethylformamide (25mg/mL) was then added and the 
solution was mixed at 350 rpm for 1 hour at 25°C. The antibody was purified using a size-
exclusion Sephadex G-25M PD-10 column (2.5 mL dead volume) and concentrated using 





5.4. Biodistribution Studies in Tumor-Bearing Mice 
 
 Pretargeting experiments were performed using all four complexes, 99mTc-FK(Tz)C, 
99mTc-FK(PEG5-Tz)CR, 
99mTc-SK(PEG5-Tz)C, and 
99mTc-DK(PEG5-Tz)C. For each complex, 
athymic nude female mice 6-8 weeks old bearing subcutaneous SW1222 xenografts (right 
shoulder, 100 -150 mm3, 14-21 days post-inoculation) were administered 125 µg. A33-TCO (in 
250 µL PBS) via tail vein injection. After 24 hours, 50-60 µCi of each complex was injected. 
After an appropriate post-injection delay (1 hour, 4 hours, and/or 8 hours), the animals were 
sacrificed using CO2 asphyxiation. The following tissues were collected; blood, tail, heart, lungs, 
liver, spleen, stomach, small intestines, large intestines, kidneys, muscle, bone, skin, and tumor. 
The tissues were then counted on a Perkin Elmer Automatic Wizard γ-counter and the percent 
injected dose per gram (%ID/g) were calculated and reported.  
 The above procedure was repeated without A33-TCO (using a blank 250 µL PBS initial 
injection) for 99mTc-FK(PEG5-Tz)CR to control for passive uptake. 
 For 99mTc-FK(Tz)C, the baseline complex, mice were sacrificed 1 hour, 4 hours, and 8 
hours post injection (n = 3 per time point).  For pretargeting with 99mTc-FK(PEG5-Tz)CR, the 
lead complex, mice were sacrificed 1 hour, 4 hours, and 8 hours post injection (n = 5 per time 
point). For the control with 99mTc-FK(PEG5-Tz)CR mice were sacrificed 4 hours post injection 
(n = 4). For 99mTc-DK(PEG5-Tz)C and 
99mTc-SK(PEG5-Tz)C, mice were sacrificed 4 hours post 







5.5. SPECT/CT Imaging Studies 
 
 Pretargeting SPECT imaging experiments were conducted on a NanoSPECT/CT Plus In 
Vivo Animal Imager. Athymic nude female mice 6-8 weeks old bearing subcutaneous SW1222 
xenografts (right shoulder, 100 -150 mm3, 14-21 days post-inoculation) were administered 125 




injected into separate mice pretargeted with the A33-TCO. Prior to imaging mice were 
anesthetized by inhalation of a 2% isofluorane: oxygen gas mixture and placed on a scanner bed. 
SPECT data was obtained for each mouse at 1 hour, 4 hour and 8 hours post injection.  
 The above procedure was repeated without A33-TCO (using a blank 250 µL PBS initial 
injection) to control for passive uptake. Was this for all or only for Tc99m FK(PEG5Tz)CR?  
Please be specific here.  
 “Pre-clicked” SPECT imaging experiments were conducted using the same instrument 
and cohort of SW1222 tumor-bearing mice used for the above pretargeting experiments. The 
mice were injected with 400 µCi of “pre-clicked” 99mTc-FK(Tz-TCO-A33)C or 99mTc-FK(PEG5-
Tz-TCO-A33)CR, anesthetized by inhalation of a 2% isofluorane: oxygen gas mixture, and 
placed on a scanner bed. SPECT data was obtained for each mouse at 1 hour, 4 hour and 8 hours 
post injection.  
 
 
5.6. Results and Discussion 
5.6.1. Blood Half-life Results 
 
 For the in vivo “click” reaction to occur, the tetrazine-containing radioligand complex 
needs to circulate in the blood pool for a sufficient period of time. If the clearance is too fast, 
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there will not be enough time for an appreciable accumulation at the target site. Consequently, 
blood half-life studies are important and were performed. These studies will help determine 
which of the complexes should be selected for imaging studies. 
 The nonlinear regressions were very strongly fit to the data (R2 = 1.00 for 99mTc-FK(Tz)C 
(Figure 34), 99mTc-FK(PEG5-Tz)CR (Figure 35), and 
99mTc-DK(PEG5-Tz)C (Figure 36); R
2 = 
0.99 for 99mTc-SK(PEG5-Tz)C (Figure 37)) and both fast and slow blood half-life clearance 
values were obtained (Table 7). It’s important to note that fast clearance represents the drug 
complexes initial circulation and excretion whereas the slow represents the gradual, subsequent 
release from tissues that absorbed the product. 
 The fast blood half-life value of 7.4 minutes is likely sufficient for the in vivo tetrazine-
transcylooctene reaction and, coupled with the biodistribution data, suggests that 99mTc-
FK(PEG5-Tz)CR is the lead compound that will be tested in subsequent imaging studies. 
 
 




Half-Life (Fast) 16.64 mins 7.37 mins 8.64 mins 4.98 mins
Half-Life (Slow) 6.38 hrs 1.90 hrs 4.91 hrs 3.31 hrs
Percent Fast 62.8% 78.9% 72.0% 77.2%




Figure 34: Non-linear regression of  99mTc-FK(Tz)C %ID/g in Blood ( n = 4; R2 = 1.00). 
 
 
Figure 35: Non-linear regression of  99mTc-FK(PEG5-Tz)CR %ID/g in Blood ( n = 4; R








Figure 37: Non-linear regression of  99mTc-SK(PEG5-Tz)C %ID/g in Blood ( n = 4; R









5.6.2. Biodistribution Studies in Healthy Mice Results 
  
 Although all four complexes exhibited high intestinal uptake, 99mTc-FK(PEG5-Tz)CR 
exhibited lower large intestine uptake (20.8±10.4 %ID/g) after 4 hours than did 99mTc-FK(Tz)C 
(65.7±22.1 %ID/g), 99mTc-SK(PEG5-Tz)C (36.8±3.5 %ID/g), and 
99mTc-DK(PEG5-Tz)C 
(50.8±9.9 %ID/g) (Table 8, Table 9, Table 10, and Table 11). The improved clearance can be 
clearly visualized by observing the comparisons between the uptake in the key excretory organs 
(the blood, liver, small intestine, large intestine, and kidneys) 30 minutes (Figure 38), 1 hour 
(Figure 39), 2 hours (Figure 40), and 4 hours post-injection (Figure 41). These results indicated 
that 99mTc-FK(PEG5-Tz)CR was the most likely candidate for providing a SPECT image with 
reduced background/non-target to target activity and a clearer tumor image. 
 
 
Table 8: Biodistribution of 99mTc-FK(Tz)C in healthy mice (n = 5 mice per time point).  
 
99mTc-FK(Tz)C %ID/g ± S.D. 99mTc-FK(PEG5-Tz)CR %ID/g ± S.D.
Organ 30 mins 1 hour 2 hours 4 hours
Blood 5.4±3.5 1.8±0.3 2.0±0.7 1.3±0.2
Tail 1.0±0.3 0.8±0.0 0.8±0.1 0.7±0.1
Heart 0.9±0.5 0.5±0.1 0.5±0.1 0.4±0.0
Lungs 2.0±0.4 1.6±0.5 1.6±0.8 1.3±0.1
Liver 20.2±8.1 18.0±4.9 13.2±4.5 5.7±1.1
Spleen 1.0±0.1 0.8±0.2 1.0±0.3 0.9±0.2
Stomach 2.5±0.6 1.7±0.7 3.3±2.0 1.5±0.8
Sm. Intestine 48.7±9.9 57.7±27.5 12.8±8.0 3.6±1.5
Lg. Intestine 0.2±0.0 0.4±0.3 45.8±13.2 65.7±22.1
Kidneys 2.9±0.5 2.4±0.2 2.7±0.3 3.2±0.3
Muscle 0.5±0.1 0.6±0.1 0.9±0.5 0.9±0.5
Bone 0.8±0.2 0.5±0.1 0.6±0.2 0.5±0.0




Table 9: Biodistribution of 99mTc-FK(PEG5-Tz)CR in healthy mice (n = 5 mice per time point). 
 
Table 10: Biodistribution of 99mTc-DK(PEG5-Tz)C in healthy mice (n = 5 mice per time point). 
 
99mTc-FK(PEG5-Tz)CR %ID/g ± S.D.
99mTc-DK(PEG5-Tz)C %ID/g ± S.D.
Organ 30 mins 1 hour 2 hours 4 hours
Blood 5.6±0.9 2.7±1.5 1.7±0.3 0.9±0.2
Tail 2.1±0.2 1.7±0.3 1.8±1.8 0.8±0.2
Heart 1.4±0.3 0.8±0.1 0.5±0.1 0.2±0.1
Lungs 2.9±0.8 2.2±0.4 1.3±0.3 0.8±0.2
Liver 10.3±1.9 13.4±3.8 3.4±2.6 2.1±1.1
Spleen 1.2±1.1 1.2±1.6 0.7±0.9 0.4±0.3
Stomach 2.5±0.7 3.1±1.1 2.7±0.5 1.7±0.9
Sm. Intestine 30.1±11.5 42.2±8.9 11.6±7.3 3.2±1.7
Lg. Intestine 0.2±0.1 0.2±0.1 25.8±10.3 20.8±10.4
Kidneys 4.2±0.6 3.6±0.5 2.7±0.4 2.3±0.3
Muscle 0.2±0.1 0.2±0.1 0.1±0.1 0.1±0.1
Bone 0.2±0.2 0.4±0.1 0.1±0.1 0.2±0.2
Skin 1.0±0.5 0.8±0.1 0.4±0.1 0.3±0.1
99mTc-DK(PEG5-Tz)C %ID/g ± S.D.
99mTc-SK(PEG5-Tz)C %ID/g ± S.D.
Organ 30 mins 1 hour 2 hours 4 hours
Blood 2.8±1.0 1.6±0.3 4.2±2.3 1.2±0.2
Tail 0.9±0.1 0.9±0.5 0.6±0.2 0.4±0.1
Heart 0.6±0.0 0.6±0.1 0.6±0.1 0.4±0.1
Lungs 1.5±0.8 1.9±0.2 1.7±0.3 1.3±0.6
Liver 11.1±9.3 4.9±2.2 5.3±4.1 1.2±0.9
Spleen 2.3±1.3 1.9±1.4 0.8±0.4 0.7±0.5
Stomach 2.8±2.9 2.6±1.1 2.0±0.7 1.4±0.2
Sm. Intestine 57.4±23.4 61.6±17.4 28.5±17.5 3.2±4.9
Lg. Intestine 1.4±2.2 4.5±8.3 38.2±3.6 50.8±9.9
Kidneys 3.9±0.6 3.8±0.5 3.1±0.4 2.8±0.6
Muscle 0.5±0.2 0.5±0.2 0.6±0.2 0.5±0.3
Bone 0.7±0.2 0.6±0.1 0.5±0.1 0.5±0.1




Table 11: Biodistribution of 99mTc-SK(PEG5-Tz)C in healthy mice (n = 5 mice per time point). 
99mTc-SK(PEG5-Tz)C %ID/g ± S.D.
Organ 30 mins 1 hour 2 hours 4 hours
Blood 1.6±0.2 1.2±0.5 0.9±0.2 0.8±0.2
Tail 0.9±0.3 0.6±0.2 0.5±0.1 0.5±0.2
Heart 0.5±0.1 0.7±0.2 0.5±0.1 0.3±0.0
Lungs 1.9±0.3 2.5±1.3 1.3±0.2 1.0±0.3
Liver 8.9±6.6 2.8±1.6 2.1±0.9 3.6±2.2
Spleen 0.4±0.2 0.6±0.0 0.4±0.1 0.3±0.1
Stomach 5.6±4.4 3.3±1.6 4.7±0.8 1.4±0.3
Sm. Intestine 44.3±8.5 37.7±21.5 15.8±17.4 2.8±0.4
Lg. Intestine 0.2±0.1 1.6±0.9 34.5±17.1 36.8±3.5
Kidneys 4.3±1.0 4.6±0.8 3.5±0.1 3.1±0.4
Muscle 0.4±0.1 0.4±0.1 0.5±0.1 0.6±0.3
Bone 0.5±0.1 0.4±0.1 0.4±0.1 0.4±0.0



















Figure 41: Biodistribution comparison in healthy mice 4 hours post-injection. 
 
5.6.3. Biodistribution Studies in Tumor-Bearing Mice Results 
 
 As observed in the biodistributions in healthy mice, all four pretargeted complexes had 
high intestinal uptake four hours post-injection, but 99mTc-FK(PEG5-Tz)CR had the lowest 
(29.0±8.5 %ID/g) (Table 12, Table 13, Table 15, and Table 16). 99mTc-FK(PEG5-Tz)CR also 
had the highest tumor uptake four hours post injection with 1.8±0.3 %ID/g compared to 1.0±0.2 
%ID/g for 99mTc-FK(Tz)C, 0.5±0.0 %ID/g for 99mTc-DK(PEG5-Tz)C, and 0.6±0.2 %ID/g for 
99mTc-SK(PEG5-Tz)C. Notably, the tumor uptake for the untargeted (i.e. lacking any A33) 
99mTc-




Tz)C and 99mTc-SK(PEG5-Tz)C, indicating that neither of complexes demonstrated appreciable 
in vivo “click” reactions and non-passive uptake and/or retention on the tumor (Table 14 and 
Figure 45). While 99mTc-FK(Tz)C and 99mTc-FK(PEG5-Tz)CR moved from the small intestine to 
the large intestine, the %ID/g was maintained on the tumor site, indicating the persistence of the 
targeting (Figure 42, Figure 43, and Figure 44).  
 Pretargeted 99mTc-FK(Tz)C had a baseline tumor:large intestine %ID/g of 1:39.9 four 
hours post-injection. One major goal of this project was to improve this ratio by both increasing 
tumor uptake and decreasing intestinal uptake. Both 99mTc-DK(PEG5-Tz)C and 
99mTc-SK(PEG5-
Tz)C failed with ratios of 1:66.2 and 1:65.8 respectively. 99mTc-FK(PEG5-Tz)CR was successful, 
however, with a ratio of 1:15.7. Despite the relatively high large intestinal uptake remaining, this 
result justified 99mTc-FK(PEG5-Tz)CR’s status as the lead complex of those tested. The full 




Table 12: 99mTc-FK(Tz)C A33-TCO pretargeting biodistribution with SW1222 tumor-bearing 
mice (n = 3) 
 
99mTc-FK(Tz)C %ID/g ± S.D.
Organ 1 hour 4 hours 8 hours
Blood 2.0±0.3 2.5±1.0 2.5±1.2
Tail 0.4±0.0 0.8±0.5 1.1±0.9
Heart 0.6±0.1 0.8±0.1 0.9±0.1
Lungs 1.4±0.0 1.3±0.1 1.6±0.4
Liver 15.6±7.3 4.1±2.0 3.1±1.1
Spleen 2.3±2.1 2.4±2.4 2.9±2.8
Stomach 5.2±1.2 4.1±1.4 3.8±1.3
Sm. Intestine 4.9±1.5 3.3±1.3 5.8±3.0
Lg. Intestine 52.1±0.9 39.6±6.6 46.1±5.9
Kidneys 1.8±0.3 2.0±0.3 2.3±0.6
Muscle 1.5±0.5 2.1±0.6 3.4±1.1
Bone 0.8±0.2 1.2±0.0 1.6±0.1
Skin 1.7±0.5 1.8±0.3 1.9±0.5




Table 13: 99mTc-FK(PEG5-Tz)CR A33-TCO pretargeting biodistribution with SW1222 tumor-
bearing mice (n = 5) 
 
Table 14: 99mTc-FK(PEG5-Tz)CR untargeted control biodistribution with SW1222 tumor-
bearing mice (n = 4) 
99mTc-FK(PEG5-Tz)CR %ID/g ± S.D.
Organ 1 hour 4 hours 8 hours
Blood 5.4±0.4 4.6±3.6 1.6±0.3
Tail 0.6±0.0 0.5±0.3 0.3±0.1
Heart 1.3±0.1 0.8±0.1 0.5±0.1
Lungs 3.5±0.4 2.3±0.4 1.0±0.2
Liver 8.4±6.8 3.9±3.1 2.1±1.6
Spleen 2.7±3.1 1.4±1.6 1.0±1.3
Stomach 9.1±2.6 9.6±2.7 9.0±8.8
Sm. Intestine 45.7±13.5 2.7±1.4 3.6±4.7
Lg. Intestine 4.7±5.1 29.0±8.5 17.5±3.1
Kidneys 4.9±0.3 3.4±0.3 2.2±0.3
Muscle 0.6±0.2 0.5±0.3 0.3±0.1
Bone 1.1±0.2 0.6±0.1 0.4±0.1
Skin 1.5±0.2 1.0±0.2 0.8±0.1
Tumor 1.8±0.1 1.8±0.3 1.7±0.3



















Table 15: 99mTc-DK(PEG5-Tz)C A33-TCO pretargeting biodistribution with SW1222 tumor-
bearing mice (n = 2) 
 
 
Table 16: 99mTc-SK(PEG5-Tz)C A33-TCO pretargeting biodistribution with SW1222 tumor-
bearing mice (n = 2) 
 















































Figure 45: A33-TCO pretargeting control (99mTc-FK(PEG5-Tz)CR injected without A33-TCO) 




Table 17: Tumor:Organ %ID/g comparison for pretargeted 99mTc-peptide-Tz complexes. 
Decreased ratios compared to 99mTc-FK(Tz)C shown as green. Increased ratios compared to 




1 hour Blood 1 : 2.0
Liver 1 : 15.1
Spleen 1 : 2.3
Sm. Intestine 1 : 4.8
Lg. Intestine 1 : 50.7
Kidneys 1 : 1.7
4 hour Blood 1 : 2.5
Liver 1 : 4.2
Sm. Intestine 1 : 3.4
Lg. Intestine 1 : 39.9
Kidneys 1 : 2.0
8 hour Blood 1 : 2.0
Liver 1 : 2.5
Sm. Intestine 1 : 4.7
Lg. Intestine 1 : 37.0
Kidneys 1 : 1.8
Time Organ 99mTc-FK(PEG5-Tz)CR pretargeting
1 hour Blood 1 : 2.9
Liver 1 : 4.6
Spleen 1 : 1.4
Sm. Intestine 1 : 24.8
Lg. Intestine 1 : 2.6
Kidneys 1 : 2.7
4 hour Blood 1 : 2.5
Liver 1 : 2.1
Sm. Intestine 1 : 1.4
Lg. Intestine 1 : 15.7
Kidneys 1 : 1.9
8 hour Blood 1 : 1.0
Liver 1 : 1.2
Sm. Intestine 1 : 2.1
Lg. Intestine 1 : 10.4
Kidneys 1 : 1.3
Time Organ 99mTc-DK(PEG5-Tz)C pretargeting
4 hour Blood 1 : 7.2
Liver 1 : 3.6
Sm. Intestine 1 : 6.9
Lg. Intestine 1 : 66.2
Kidneys 1 : 5.1
Time Organ 99mTc-SK(PEG5-Tz)C pretargeting
4 hour Blood 1 : 2.0
Liver 1 : 1.3
Sm. Intestine 1 : 4.6
Lg. Intestine 1 : 65.8
Kidneys 1 : 5.8
Time Organ 99mTc-FK(PEG5-Tz)CR control
4 hour Blood 1 : 5.4
Liver 1 : 7.2
Sm. Intestine 1 : 6.1
Lg. Intestine 1 : 42.5
Kidneys 1 : 6.3
111 
 
5.6.4. SPECT/CT Imaging 
 
 As expected, when 99mTc-FK(Tz)C was “pre-clicked” with A33-TCO and injected into an 
SW 1222 tumor-bearing mouse the tumor was clearly imaged with SPECT/CT six hours post-
injection (Figure 46). This control confirmed the targeting of the radiolabeled MAb complex and 
established a baseline for comparison against pretargeted images. When another tumor-bearing 
mouse was pretargeted with A33-TCO and injected with 99mTc-FK(Tz)C 24 hours later (Figure 
47), the tumor was clearly delineated, indicating a successful in vivo Tz-TCO “click,” but high 
uptake in the intestines compromised the quality of the image. The control, wherein a tumor-
bearing mouse was injected with PBS followed 24 hours later by 99mTc-FK(Tz)C and SPECT/CT 
imaging four hours post-injection (Figure 48), confirmed that the accumulation in the 
pretargeted tumor was not due solely to passive effects. 
 The images obtained for 99mTc-FK(PEG5-Tz-TCO-A33)CR (Figure 49), 
99mTc-
FK(PEG5-Tz)CR with pretargeted A33-TCO (Figure 50) and untargeted 
99mTc-FK(PEG5-Tz)CR 
(Figure 51) were comparable to those obtained using 99mTc-FK(Tz)C despite the improved 
tumor:background ratios previously discussed. This indicates that while 99mTc-FK(PEG5-Tz)CR 
represented an incremental improvement over the original complex tested, 99mTc-FK(Tz)C, its 
intestinal uptake remains too high for translation to the clinic. In both cases, the in vivo “click” 
reaction was confirmed with SPECT/CT, but complexes with more favorable pharmacokinetic 
and clearance characteristics will need to be investigated. 
 The tumors could not be effectively delineated in either of the SPECT/CT images 
obtained from 99mTc-DK(PEG5-Tz)C or 
99mTc-SK(PEG5-Tz)C pretargeted with A33-TCO 
(Figure 52 and Figure 53). These images were essentially identical to the untargeted controls 
(Figure 54 and Figure 55). Given the minimal tumor uptakes observed for these complexes in 
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the pretargeted biodistributions previously discussed, this is hardly surprising. This result is most 
likely the result of lower in vivo stability and confirms that 99mTc-FK(PEG5-Tz)CR was an 
appropriate choice as the lead compound.  
 
Figure 46: “Pre-clicked” 99mTc-FK(Tz-TCO-A33)C (6 hrs) (Left to right: full scan; sagittal slice 
intersecting with tumor center; coronal slice intersecting with tumor center; axial slice 





Figure 47: 99mTc-FK(Tz)C and A33-TCO in vivo click (4 hrs) (Left to right: full scan; sagittal 
slice intersecting with tumor center; coronal slice intersecting with tumor center; axial slice 





Figure 48: 99mTc-FK(Tz)C control (4 hrs) (Left to right: full scan; sagittal slice intersecting with 




Figure 49: “Pre-clicked” 99mTc-FK(PEG5-Tz-TCO-A33)CR (8 hrs) (Left to right: full scan; 
sagittal slice intersecting with tumor center; coronal slice intersecting with tumor center; axial 




Figure 50: 99mTc-FK(PEG5-Tz)CR and A33-TCO in vivo click (4 hrs) (Left to right: full scan; 
sagittal slice intersecting with tumor center; coronal slice intersecting with tumor center; axial 




Figure 51: 99mTc-FK(PEG5-Tz)CR control (4 hrs) (Left to right: full scan; sagittal slice 
intersecting with tumor center; coronal slice intersecting with tumor center; axial slice 




Figure 52: 99mTc-DK(PEG5-Tz)C and A33-TCO in vivo click (4 hrs) (Left to right: full scan; 
sagittal slice intersecting with tumor center; coronal slice intersecting with tumor center; axial 
slice intersecting with tumor center). 
 
 
Figure 53: 99mTc-DK(PEG5-Tz)C control (4 hrs) (Left to right: full scan; sagittal slice 
intersecting with tumor center; coronal slice intersecting with tumor center; axial slice 




Figure 54: 99mTc-SK(PEG5-Tz)C and A33-TCO in vivo click (4 hrs) (Left to right: full scan; 
sagittal slice intersecting with tumor center; coronal slice intersecting with tumor center; axial 





Figure 55: 99mTc-SK(PEG5-Tz)C control (4 hrs) (Left to right: full scan; sagittal slice 
intersecting with tumor center; coronal slice intersecting with tumor center; axial slice 




  The biological data obtained confirmed the in vivo “click” reaction for 99mTc-FK(Tz)C 
and 99mTc-FK(PEG5-Tz)CR but not for 
99mTc-DK(PEG5-Tz)C or 
99mTc-SK(PEG5-Tz)C. 
Although the tumor:intestinal uptake was significantly reduced for the lead complex, 99mTc-
FK(PEG5-Tz)CR, compared with the original complex tested, 
99mTc-FK(Tz)C, it remained too 
high for translation to the clinic.  
 The failure of 99mTc-DK(PEG5-Tz)C and 
99mTc-SK(PEG5-Tz)C to produce SPECT/CT 
images with well delineated tumors could be a function of their blood-half lives and/or in vivo 
stability. 99mTc-DK(PEG5-Tz)C had a longer blood half-life than did 
99mTc-FK(PEG5-Tz)CR, but 
99mTc-SK(PEG5-Tz)C had a shorter blood-half-life. This indicates that the blood half-life could 
explain the failure of 99mTc-SK(PEG5-Tz)C but not 
99mTc-DK(PEG5-Tz)C. All of the pretargeted 
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images showed activity in the thyroid, indicating at least some degradation. While this was 
present for the lead complex as well as the failed complexes, it is possible that the 99mTc-
DK(PEG5-Tz)C and 
99mTc-SK(PEG5-Tz)C degraded further than did 
99mTc-FK(PEG5-Tz)CR, 










































 A series 99mTc imaging agents with tri- or tetra-peptide N3S ligands and appended Tz 
moieties were successfully synthesized and characterized along with their cold Re analogs. The 
first complex tested in vivo, 99mTc-FK(Tz)C, successfully imaged an SW1222 xenografted tumor 
pretargeted with A33-TCO. This was a promising result, but shared the high background 
observed by Garcia et al. with 99mTc-HYNIC-Tz.115 The subsequent strategy to find a more 
hydrophilic alternative, thereby promoting renal clearance and lowering intestinal uptake, was 
successful with the lead complex, 99mTc-FK(PEG5-Tz)CR, as demonstrated by the Log P value 
and the biodistributions in healthy and tumor-bearing mice. The other two complexes tested, 
99mT-DK(PEG5-Tz)C and 
99mTc-SK(PEG5-Tz)C were more hydrophilic, but had lower 
tumor:background uptake and could not delineate the tumors in pretargeted SPECT/CT images. 
 Despite the improved tumor:intestinal uptake (down to 1:16 for 99mTc-FK(PEG5-Tz)CR 
from 1:40 %ID/g for 99mTc-FK(Tz)C), the SPECT/CT image was not greatly improved. 
Consequently, the search for additional Tz-bearing 99mTc complexes with more favorable 
characteristics is on-going. 
  Although this work did not produce a viable candidate for use in the clinic, it represents 
one more example of a successful in vivo “click” that made use of the bioorthogonal IEDDA 
reaction. The IEDDA reaction has made small molecule pretargeting considerably more 
accessible and will continue to facilitate the development of now radiopharmaceuticals in the 


































 Future work will focus on finding 99mTc ligand systems that can both accommodate the 
addition of a Tz moiety and provide more favorable pharmacokinetic and clearance 
characteristics. If further peptide ligand systems are pursued, additional lysine residues as well as 
more positively charged residues could promote renal clearance. Alternative Tz moieties can also 
be explored to both improve clearance properties and in vivo stability. 
 Additionally, any ligand system developed should be compatible for use in a kit wherein 
the Tz-bearing ligand would simply require the addition of 99mTcO4
- under mild conditions for 
ease of use in the clinic. With the pretargeting methodology already requiring a two-step 
administration during treatment, any complex synthetic procedure would preclude translation. 
 Despite the difficulties that have been encountered in developing Tz-bearing 99mTc 
imaging agents to take advantage of the IEDDA “click” reaction both by this group and others, 
there is no reason to expect that these will not be overcome in due time. With the plethora of 
99mTc complexes currently used in the clinic and the continued maturation of pretargeting, the 
scientific and commercial possibilities of making use of IEDDA “click” reactions for improved 
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